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( ABSTRACT 
Objective: Using prescription claims data, the objectives of this study were: (1) to 
compare the propo1iion of variation in cost of pharmaceuticals that could be explained by 
available demographic variables and plan characteristics within various therapeutic 
categories; (2) to examine the relationships among plan characteristics and cost of 
pharmaceuticals; and (3) to evaluate whether utilization differed among various 
demographic variables and plan characteristics after controlling for appropriate 
covariates. 
Design: Retrospective, cross-sectional study. 
Data Collection: Data for this study were obtained from 1996 prescription claims 
information for the commercial population administered by a Rhode Island-based 
pharmacy benefit management company. Six therapeutic categories with the highest 
expenditures were analyzed. 
Methodology: Information on claims for six drug categories was extracted using 
database management software. Statistical analyses utilizing multiple regression and 
analysis of covariance were carried out. 
Results: Plan characteristics out-performed demographic variables sixteen-fold for all 
drug categories combined in explaining variance in cost of pharmaceuticals among plan 
enrollees. Significant associations were found among plan characteristics and cost of 
pharmaceuticals. Utilization differed among various demographic variables and plan 
ii 
( characteristics after controlling for average wholesale price and days supply. 
Demographic variables included age, gender, place of employment and place of residence 
while plan characteristics included variables such as co-payment, mode of payment, 
fonnulary status and pham1acy type. 
Conclusions: The results obtained in this study have practical significance in the 
detennination of capitation rates when utilization history of prospective members is not 
available. In this situation phamrncy benefit managers may have to set capitation rates 
based solely on eligibility data. In addition to highlighting the importance of utilization 
history in setting capitation rates for new enrollees the study results have other 
ramifications. PBMs contract with commercial clients to provide pharmacy benefits to 
their employees irrespective of their occupation. Significant differences in utilization 
among the members based on place of employment suggest that benefit managers should 
consider differentiating capitation rates according to their clients' business. Finally, the 
data from this study indicated that commercial members residing in Tennessee had the 
lowest level of drug utilization among all states evaluated. The fact that one PBM 
manages over 80% of the TennCare prescription program along with a significant 
commercial client base suggests that a "spillover effect" may exist. 
Results may be helpful in understanding some of the factors associated with cost of 
pharmaceuticals. For example, the inverse relationship of pharmaceutical cost with 
eligible days may be helpful in budgeting program costs while the non-significant 
association of pharmaceutical cost with number of members eligible suggests a lack of 
importance of group size in negotiating pharmacy benefit contracts. 
Ill 
Differences in utilization among various co-payment levels suggest the effectiveness of 
different co-payment levels in promoting use of generic products. Lower utilization found 
under capitation may be encouraging to those PBMs accepting a capitation method of 
reimbursement. Association of closed fomrnlaries with higher utilization indicates the 
importance of adjusting cost data for rebates before evaluating forrnulary strategies. 
Finally, differences in utilization between independent and chain pharmacies suggest the 
importance of careful provider contract negotiation. 
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( PREFACE 
This work has been prepared in accordance with the manuscript format option for thesis 
preparation, as outlined in section 11-3 of the Graduate Manual of the University of 
Rhode Island. Contained within is a body of work divided in two sections. 
Included within section I are two manuscripts, containing the findings of the research 
which comprise this thesis. These manuscripts are presented in the fomiat required by the 
journal to which they will, or have been, submitted. 
Section II is comprised of an appendix containing a SAS program. This thesis closes with 
a complete listing of all references cited in this thesis, arranged in alphabetic order by the 
author ' s last name. 
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SECTION I 
( 
MANUSCRIPT I 
The Effect of Demographics on the Cost of Phamrnceuticals in a Private Third-Party 
Prescription Program 
2 
( ABSTRACT: 
I 
Objective: The primary objective of this study was to compare variance in cost of 
phannaceuticals explained by demographic variables with variance explained by plan 
characteristics within various therapeutic categories using prescription claims data. The 
secondary objective was to examine differences in utilization among demographic 
variables after controlling for covariates. 
Design: Retrospective, cross-sectional study. 
Data Collection: Data for this study were obtained from 1996 prescription claims 
information for the commercial population administered by a Rhode Island-based 
pham1acy benefit management company. Six therapeutic categories with the highest 
expenditures were analyzed. 
Methodology: Information on claims for six drug categories was extracted using 
database management software. Statistical analyses utilizing multiple regression and 
analysis of covariance were carried out. 
Results: Plan characteristics out-performed demographic variables sixteen-fold for all 
drug categories combined in explaining variance in cost of pharmaceuticals among plan 
enrollees. Significant differences in utilization were found among various demographic 
variables after controlling for average wholsale price and days supply. 
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( Conclusions: The results obtained in this study have practical significance in the 
detern1ination of capitation rates when utilization history of prospective members is not 
available. In this situation PBMs may have to set capitation rates based solely on 
eligibility data. In addition to highlighting the importance of utilization history in setting 
capitation rates for new enrollees the study results have other ramifications. PBMs 
contract with commercial clients to provide pharmacy benefits to their employees 
irrespective of their occupation. Significant differences in utilization among the members 
based on place of employment suggest that benefit managers should consider 
differentiating capitation rates according to their clients' business. Finally, the data from 
this study indicated that commercial members residing in Tennessee had the lowest level 
of drug utilization among all states evaluated. The fact that one PBM manages over 80% 
of the Tenn Care prescription program along with a significant commercial client base 
suggests that a "spillover effect" may exist. 
Key Words: 
Cost of pharmaceuticals, Demographics, Plan characteristics, Utilization, Confounding 
variables, Prescription claims data, Capitation rate, PBM, Pharmacy benefit, Multiple 
regression, Analysis of covariance, Place of employment 
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INTRODUCTION: 
Managed care has become an ever-increasing force in the health care market. The most 
recent Foster Higgins survey of employer-sponsored health plans found that 85% of 
workers at firms with 10 or more employees are now enrolled in managed health plans, a 
significant increase from 1996 figures of77%.[l] In 1996, 94 % of commercial/group 
members had a phamrncy benefit, a percentage that is expected to remain stable through 
1999. [ 1] Over the last few decades, there has been a constant awareness of the rapid 
escalation in prescription drug costs. These increases can be explained in large part by 
therapeutic innovations, increased utilization related to demographics and increased 
coverage under drug benefit programs. Prescription drugs are an essential part of current 
medical treatment technology, which is why virtually all private insurance plans, 
managed care organizations and state Medicaid programs cover prescription drugs for 
their enrollees. 
The emergence of pharmacy benefit management companies (PBMs) constitutes a major 
structural change that has occurred in the distribution of phannaceuticals during the 
1990s.[2] Because monitoring, managing, and implementing a pharmacy benefit requires 
a considerable commitment of time and resources, many health maintenance 
organizations (HMOs) and self-insured employers tum to PBMs for assistance in 
managing all or part of their pharmacy benefit programs. Almost 90% of the employers 
responding to a trends & forecasts survey reported that they take an active role in 
managing their pharmacy benefits. Of those, 70.6 % contracted directly with a PBM, 
5.9% said their providers contracted with a PBM and 23.5 % reported that their health 
5 
plan provides phannacy benefit without referring to a PBM.[1] Some analysts expect that 
PBMs will control nearly three-quarters of the U.S. phannaceutical market within the 
next five years.[3] 
Prescription drug benefits are one of the few areas in health care in which health plans 
have continued to maintain and manage financial risk rather than share it with providers. 
PBMs provide a variety of services designed to influence outpatient prescription drug 
utilization and costs. Employers and insurers contract with PBMs in an effort to provide 
accessible and cost-effective benefits to their members. PBMs are sometimes offered 
risk-based capitation payment progran1s as an alternative to fee-for-service (FFS) for a 
variety of population groups and benefit packages. Contracts based on capitation 
reimbursement limit the payers' financial risk by setting a fixed dollar amount per 
member per unit of time. The PBM must provide all the contracted services for the 
specified amount of money or suffer a financial loss. 
With capitation payments linked to HMO premiums, and with HMO premiums dropping 
in response to market pressure from employers, PBMs are coming under increased 
financial pressure to reduce their costs. It is essential that the capitation rates accurately 
reflect actual drug utilization if the reimbursement is to be fair to both the provider and 
the payer. Previous research has found that factors affecting use of health services are not 
limited to the characteristics of the service but often extend to the characteristics of the 
user.[ 4] Those persons pricing, selling and administering prescription drug benefit 
programs should be aware of the effects of members' demographics on their prescription 
6 
benefit costs. Amendments to HMO laws in 1981 have allowed the adjustment of 
capitation rates for demographic variables of the subscribers.[5] There is a debate about 
whether the usual underwriting factors such as age, sex, occupation and residence are 
sufficient for establishing annual premiums.[6] A study examining demographic variables 
as predictors of annual outpatient expenditures concluded that demographic 
characteristics perform very poorly as underwriting factors.[7] 
Still, the extent of drug use by patients of all ages is an important issue. Age-specific 
utilization rates have shown to be the most important detem1inant of overall expenditures 
on prescription drugs.[8] While the consequences of extensive drug therapy have 
attracted much attention, few definitive studies have been carried out to examine the 
number, types of drugs prescribed, and its association with cost within different age 
groups. Cross-sectional studies have consistently indicated that prescription drug use 
increases with age.[9] For example, one study assessing the relationship of demographics 
to prescription drug use among elderly Pennsylvanians who had enrolled in the 
Pharmaceutical Assistance Contract for the Elderly (PACE) program found that 
prescription utilization rises with age.[10] In another study, annual drug expenditures 
varied significantly by age and sex categories.[11] These qualitative differentials have 
been validated in national data [ 12], which show mean expenditures for women to be 
54% above men, and children's expenditures only half that of males. Gender differentials 
in prescription drug use have been reported to persist even after controlling for disease 
severity, the nature of the medical problem (acute or chronic), age, and other factors 
considered to be medically relevant.[13] Specifically, both age and sex appear to be 
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( strongly associated with antihypertensive, antidepressant and H2-antagonist drug 
use.[14, 15, 16] 
Employment is associated with a lower incidence and prevalence of drug use for men but 
not for women.[17] While employment has a differential effect on men's and women's 
drug use, it does not affect the extent of prescription drug use.[17] As the risk factor 
levels for cardiovascular disorders, depression and ulcers differ among occupation 
groups, further research is needed to detennine how people in diverse occupations differ 
in their prescription drug use. 
In 1993, Smith found that the cost of pharmaceutical services was correlated with 
geographic region.[18] However, other studies have found little regional variation in drug 
use based on age-gender adjusted prescription costs.[19] 
There is presently an increasing interest in the assessment of ambulatory health care 
databases. Much of this interest is centered around health-system administrators who 
wish to better understand their cost structures in an attempt to control costs and improve 
quality of care.[20] Also, research has shown that outpatient services are generally more 
predictable than inpatient services.[7] 
PBMs have emerged as a key manager of information in today' s world of health care. 
PBMs can link networks of pharmacies through tele-communication lines to a processor 
for the point-of-service (POS) evaluation of prescription claims. Inforniation is 
8 
I transmitted electronically to the pharmacy about member eligibility, benefit coverage and 
prescription pricing. The resulting central claims database becomes a rich source of 
information for both the PBM and the payer about cost, utilization and overall benefit 
management. Claims data have traditionally been used for accounting purposes. 
However, as the structure of PBMs has evolved, many have begun to build additional 
data repositories. This has allowed easy access and manipulation through the use of high 
level languages such as standard query language (SQL). 
Claims data can provide accurate information on drugs dispensed. In addition, claims 
data is not subject to the recall problems that are found with self-reported data and can 
provide a more representative picture of drug utilization than provider-based studies. [21] 
Though these data sets are somewhat limited in that they often do not consistently 
identify the prescribing physician and do not have accurate diagnosis information, they 
do provide excellent population profiles of drug utilization. These profiles, once created, 
can be easily supplemented with additional information to improve their utility. 
Using prescription claims data, the objectives of this study were: (1) to compare the 
proportion of variation in cost of pharmaceuticals that could be explained by available 
demographic variables and plan characteristics within various therapeutic categories; and 
(2) to evaluate whether utilization differed among various demographic variables after 
controlling for appropriate covariates. 
9 
( METHODOLOGY: 
Study Description: 
Data for this study were obtained from prescription claims infom1ation compiled during 
1996 for the commercial population administered by MIM Health Plans, Inc., a Rhode 
Island-based pharmacy benefit management company. These data were collected from 
pharmacies at the point of service during the routine filling of commercial members' 
prescriptions. Data elements confom1ed to National Council on Prescription Drug 
Processing (NCPDP) standards for pharmacy claims adjudication. Algorithms to assure 
data accuracy were applied at the point of service and retrospectively by the PBM. All 
data were blinded as to patient name assuring confidentiality of medical information. The 
study was approved by the University of Rhode Island Institutional Review Board on 
human subjects. 
Measures: 
Each record in a claims file represented a prescription dispensed to a member. The 
information in the record included: pharmacy identification (NABP) number, date of 
service, national drug code (NDC) for the medication, Generic Product Identifier (GPI), 
generic name, number of prescriptions, quantity dispensed, amount paid by the member 
(co-payment), amount reimbursed to the pharmacy provider, member identification 
number, gender, age, carrier name, account name, group name, and number of days 
supply. 
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( NABP number was used to link claims files with phamrncy files to get information on the 
name of the pharn1acy and the state in which it is located. The unique combination of 
caITier, account and group representing a particular plan was used to determine place of 
the members ' employment. Based on the National Occupational Classification [22], 
members were assigned to one of the following employment categories : management, 
commerce, health, social sciences, lawyers & educators, art, sales & services, trade & 
transport, primary industries, manufacturing and contractors. 
The database contained no information on the member's place of residence, 
race/ethnicity, educational level and income so measuring the effect of these 
demographic variables on the cost of pharmaceuticals was not possible. However, 
members are likely to present their prescriptions in the vicinity of their homes. 
Therefore, pharmacy location was used as a proxy variable for their residences. 
In addition to demographic information, a file on member eligibility contained each 
member's enrollment history. Each member was identified by a member number and 
may be the original enrollee (subscriber) or a dependent . Questions on continuity of 
coverage can be answered from the information in this file, which maintains a temporal 
view of the member' s activity within the system. Member identification number was 
utilized as a common field to link claims files with eligibility files to determine the 
members' eligibility. 
11 
( Because claims data were never structured to answer specific questions of this study, 
algorithms were designed for extracting appropriate subsets of claims using database 
management software (Dbase 2.6). The Generic Product Identifier codes (Medispan, Inc.) 
were used to divide prescription drugs into major therapeutic categories. Using pre-
collected data necessitated careful selection and examination of the data. Claims files 
were indexed with reversed claims, marked manually and deleted to ensure that the data 
for analysis did not include any denied or reversed claims. A claim reversal occurs when 
a pharmacist has to resubmit a claim due to entering the wrong information in the system 
such as a coding error or a claim with a missing drug identification code. The error is 
corrected by entering a claim identical to the first claim but with negative financial 
values. The third record reflects the correct information. 
Six therapeutic categories with the highest expenditures during fiscal year 1996 were 
selected for the analysis. These included calcium channel blocking agents, angiotensin 
converting enzyme (ACE) inhibitors, lipotropics, antidepressants, histamine H2-blockers, 
and beta-adrenergic blocking agents . 
Member-specific prescription data were extracted from the computerized records for the 
period of January 1 through December 31, 1996. All members who received at least one 
prescription for these therapeutic drug categories were included in the analysis. The total 
value of claims used in the analysis was $1 .5 million with an average of$ 0.15 per 
member per eligible day. 
12 
( Outline of Statistical Analysis: 
The SAS program for windows (version 6.12) was used for all statistical analyses. 
Frequency analysis for categorical variables and univariate analysis for continuous 
variables was carried out. PROC UNIVARIATE and PROC PLOT were perfonned to 
assess the assumptions of normality, linearity and homoscedasticity. 
Members differed in number of days eligible dming fiscal year 1996. There were cases 
where the utilization data did not reflect a full year's experience. To adjust for this, the 
cost of prescription was divided by eligible days resulting in an estimate of the amount 
that members cost the plan per day. Therefore, the cost per member per eligible day was 
used as the dependent variable for statistical analyses. Frequency analysis revealed 
relatively few claims in states other than Tennessee. To avoid the problem of small 
numbers and unstable estimates, claims from states other than Tennessee were combined 
to form one category of "other states". Other states included: Rhode Island, Virginia, 
Georgia, New Jersey etc. Depending upon the drug category that was reviewed, the same 
strategy was followed for place of employment. For example, claims for members 
employed in management, commerce, social sciences, lawyers, education, art, primary 
industries and trade & transport businesses were combined to form one category of 
"other" and compared with those employed in manufacturing, contractors, health, and 
sales and services businesses for Ca-channel blockers. 
Claims for Ca-channel blockers, lipotropics, ACE inhibitors and beta-blockers were 
combined and designated as claims for cardiovascular drugs. Claims for the remaining 
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( two drug categories (antidepressants and histamine HZ-blockers) were also combined. 
Finally claims for all six-drug categories were combined which resulted in nine sets of 
claims for analysis after considering each drug category individually. 
Three sets of multiple regression analyses were carried out. The first set using PROC 
REG was perforn1ed to detennine the proportion of variation in the cost of 
phannaceuticals that could be explained by age, gender, location and place of 
employment for the six drug categories and their combinations. For these analyses, 
dummy variables were used for gender, location and place of employment. 
The gender variable was dummy coded as male=l and female=O. Location was dummy 
coded as Te1messee=l and other states=O. Dummy coding for place of employment 
differed for some drug categories. For example four dummy variables were used ( Xl, 
X2, X3, X4) for place of employment in Ca-channel blockers; Manufacturing (Xl=l, 
X2=0, X3=0, X4=0), Health (Xl=O, X2=1, X3=0, X4=0), Sales & Services (Xl=O, 
X2=0, X3=1, X4=0), Contractors (Xl=O, X2=0, X3=0, X4=1), and Other (Xl=O, X2=0, 
X3=0, X4=0). Interaction terms were added to detennine whether the explained variance 
could be significantly improved by accounting for interaction effects between the 
independent variables. Variance inflation factor tests were used to determine if 
multicollinearity problems existed. 
The second set of multiple regression analyses was carried out to examine the proportion 
of variation in the cost of pharmaceuticals that could be explained by plan characteristics. 
14 
\ 
The independent variables included in the analyses were number of days eligible, number 
of members eligible, average wholesale price, out-of-pocket expense, number of days 
supply and quantity dispensed. Variance inflation factor tests were used to determine if 
problems with multicollinearity existed. 
The third set of multiple regression analyses was carried out to examine the proportion of 
variation in the cost of pharmaceuticals that could be explained by both demographic 
variables and plan characteristics. 
In order to ensure a valid comparison, analyses of covariance (ANCOV A) were used to 
evaluate the differences in utilization among demographic variables using cost of 
pharmaceuticals per member per eligible day as the dependent variable. ANCOV A 
allowed us to hold factors that might influence the cost of pharmaceuticals constant and 
to observe the differences only due to patient demographics. The last two digits of the 
member identification number facilitated the separation of claims of subscriber (card 
holder) from their dependents. For testing our hypotheses regarding place of employment 
and cost of pharmaceuticals, only claims by subscribers were selected. Age was analyzed 
after being categorized into five groups; 1-5, 6-20, 21-40, 41-64, and >64 years old. 
The control variables were member age, group size, average wholesale price and number 
of days supply. Changes in the average wholesale price (A WP) that manufacturers charge 
for each unit of their product is an indicator of price inflation while days supply reflects 
the quantity dispensed. In some cases we found significant interaction between variables 
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of interest (grouping variables) and the covariate indicating violation of the assumption of 
homogeneity of regression . Effect sizes of interactions between grouping variables and 
the covariate were calculated. To understand the relative differences between groups, we 
also computed least square adjusted means which held the covariates constant. A value of 
p <=0.05 was chosen as the a priori level of significance. 
RESULTS: 
Sample Description: 
Table 1 provides information about the characteristics of enrollees. There were 29 ,211 
subscribers (card holders) representing 64,815 enrollees eligible during fiscal year 1996. 
33, 131 prescription records for six drug categories were evaluated. The mean age of 
enrollees was 31.5 years. Females comprised 52.8 % of the eligible population and males 
comprised 47.2 %. Subscribers were mainly employed in health (39.8%), sales and 
services (17.7%) and manufacturing (10.3%). 
Results of Multiple Regression Models: 
Table 2 summarizes results of the multiple regression using cost per member per eligible 
day as a dependent variable and age, gender, location and place of employment as 
independent variables. The regression models were significant at the 0.001 level of 
significance for all drug categories and their combinations. The explained variance in the 
cost of pharmaceuticals by therapeutic category ranged from 1.6% to 13.7 %. This 
variance was lowest for antidepressants and highest for H2-blockers. Interactions among 
independent variables were added in the models to improve the explained variance. For 
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example, interactions among gender, location, and place of employment were included 
in the model. Addition of interaction terms did not significantly improve the explained 
variance with the exception of all drug categories combined. Explained variance for all 
drug categories combined in presence of the interaction terms was 9.6% in comparison to 
3.9% without the addition of interaction terms. The improvement in explained variance 
was associated with multicollinearity problems as indicated by variance inflation factors 
and high standard errors of beta coefficients. Keeping the problems of multicollinearity in 
mind, regression analyses were carried out excluding interaction terms. For the purpose 
of this study, cost of pharmaceuticals was defined as the dollar expenditure per member 
per eligible day for prescription drugs. 
Age was positively associated with the cost of pharmaceuticals for all drug categories 
except for beta-blockers and antidepressants. Males were positively associated with the 
cost of pharmaceuticals for Ca-channel blockers and beta-blockers and negatively 
associated with lipotropics and antidepressants. This relationship was not significant for 
ACE inhibitors and H2-blockers. Residence in the state of Tennessee, which comprised 
the majority of our population, was negatively associated with cost of pharmaceuticals 
for all drug categories. 
Cost of pharmaceuticals was positively associated with manufacturing employees versus 
employees of other businesses for Ca-channel blockers, lipotropics and H2-blockers. It 
was negatively associated for antidepressants. The relationship was not significant for 
ACE inhibitors and beta-blockers. Cost of pharmaceuticals was negatively associated 
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with members employed in the health professions for Ca-channel blockers, ACE 
inhibitors and beta-blockers. The relationship was insignificant for lipotropics, H2-
blockers and antidepressants. 
Cost of phannaceuticals was negatively associated with sales and services employees for 
all drug categories except for the H2-blockers, where the relationship was nonsignificant. 
Cost of pharmaceuticals was positively associated with contracting and commerce 
employees for Ca-channel blockers and antidepressants respectively. Cost of 
pharmaceuticals was positively associated with management employees for ACE 
inhibitors and H2- blockers. 
Table 4 provides the results of multiple regressions using cost per member per eligible 
day as a dependent variable and plan characteristics as independent vaiiables for six drug 
categories and their combinations. Regression models were significant at the 0.001 level 
of significance. Explained variance ranged between 34 % to 87 %. Explained variance 
was lowest for beta-blockers and highest for antidepressants. Small variance inflation 
factors indicated absence of multicollinearity. (table 5) 
Table 6 and table 7 summarizes results of multiple regressions using both demographic 
variables and plan characteristics for six drug categories and their combinations. 
Explained variance did not significantly vary from using plan characteristics alone as 
independent variables. 
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Results of Analyses of Covariance: 
For the purpose of this study, utilization was defined as the average dollar expenditure 
per member per eligible day for prescription drugs. Average wholesale price and days 
supply were selected as covariates because controlling for age and number of members 
eligible did not significantly improve the model fit (R2). In some cases, interactions 
between average wholesale price and grouping variables as well as days supply and 
grouping variables were significant. Effect sizes of these interactions were calculated. 
Values of these effect sizes, which approached zero, allowed the use of average 
wholesale price and days supply as covariates without violating the assumptions of 
ANCOV A.(table 14, 15) Least square means (LSMEANS) adjusted for average 
wholesale price and days supply were examined. 
There were significant differences in utilization among members in various age groups. 
Members in the 65 and older age group were the highest utilizers of all drug categories 
except for beta-blockers and antidepressants. (table 9) 
There were significant differences in utilization between males and females. Males were 
higher utilizers of all drug categories except for lipotropics and antidepressants. For 
these two categories, females showed significantly higher utilization. (table 10) 
There were significant differences in utilization among members residing in Tennessee 
and those residing in other states. Considering all of the states together with the exception 
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ofTe1messee, residents of Tennessee were the lowest utilizers for all drug categories. 
(table 11) 
Table 12 presents the results of analyses of covariance using cost per member per eligible 
day as a dependent variable and place of employment as an independent variable for six 
drug categories and their combinations. 
There were significant differences in utilization among members employed in different 
occupations. For the six drug categories combined, members employed in contracting 
were the highest utilizers and members employed in health care were the lowest utilizers. 
Members employed in art, trade & transport, primary industries and social sciences were 
the highest utilizers of cardiovascular drugs while those employed in health care were the 
lowest utilizers. Combining H2-blockers and antidepressants together, members 
employed in art, trade & transport, primary industries and social sciences were the 
highest utilizers while those employed in commerce were the lowest utilizers. 
Two-way analyses of covariance were conducted using cost per member per eligible day 
as a dependent variable with place of employment and gender as the independent 
variables. For the six drug categories combined, males employed in contracting were the 
highest utilizers and females employed in health care were the lowest utilizers. Looking 
at cardiovascular drugs as a combined category, females employed in art, trade & 
transport, primary industries and social sciences were the highest utilizers and males 
employed in health care were the lowest. Combining antidepressants and H2-blockers, 
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( males employed in health care were the highest utilizers while males employed in 
manufacturing were the lowest. (table 13) 
DISCUSSION: 
Several limitations should be considered before discussing the results of this study. The 
major limitation relates to the comprehensiveness of the data. The database includes only 
drug products covered by the drug benefit plans. Thus, non-prescription drugs, drug 
samples and non-formulary drugs (when paid for with cash by members) are typically not 
included. In addition, if a prescription drug is less expensive than the member's 
copayment, the member may pay cash and a claim may not be recorded. Underreporting 
occurs with most third-party prescription databases [23] and may be a limitation in this 
study. Lastly, prescriptions filled from "out-of-network" pharmacies were not captured. 
The study may also be limited in terms of generalizability. It is possible that the general 
population behaves differently from the study population. Therefore, careful 
consideration should be used before extrapolating these findings beyond the study 
population. Although our data are cross-sectional and do not allow causal inferences, 
there are several possible explanations for the findings of the study. 
One of the objectives of the study was to examine the proportion of variation in cost of 
pharmaceuticals that could be explained by demographic variables. In effect, we wanted 
to evaluate whether demographic variables could be used to determine capitation rates for 
new enrollees. Place of employment was selected as one of the independent variables in 
the regression models. Pharmacy benefit managers provide prescription drug benefits to 
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( employees of commercial clients irrespective of members' occupation. As a result, place 
of employment becomes a more relevant variable to evaluate than occupation. 
In spite of the large sample size (N=33, 131 ), available demographic variables only 
explained 3.9 % of variance in cost of pharmaceuticals for all drug categories combined. 
A study that used multiple regression analysis to determine the proportion of variance in 
aggregated clinic, referral and hospital costs found that 20 % of variation in cost could be 
explained by sex and coverage type of the enrollees.[5] The lowest explained variance 
among all therapeutic categories was for antidepressants (1.6%). This may be explained 
in part by the availability ofrelatively new products, increased public awareness, 
acceptance of depression as a disease, physician education programs and mass media 
attention. [24] 
Our study demonstrated that plan characteristics accounted for most of the variance 
unexplained by demographic variables. These plan characteristics were comprised of 
number of days eligible, number of members eligible, average wholesale price of drugs 
dispensed, out-of-pocket expense, number of days supply and quantity dispensed. When 
taking only plan characteristics into account, the explained variance for antidepressants 
increased to 87%. These results strongly indicate that data on service use and cost 
experience of individuals to be covered by a risk-based capitation payment program are 
much better predictors of costs of pharmaceuticals than simple demographics. Wouters in 
1991 found that prior-year outpatient drug expenditures were the strongest predictors of 
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future annual outpatient drug expenditures and thus, should be considered as important 
infonnation to include in detennination of capitation rates.[7] 
Effect of Member Demographics on Costs of Pharmaceuticals: 
Age: 
Members over the age of 65 were the highest utilizers of all drug categories except for 
beta-blockers and antidepressants. This is consistent with previous studies that show 
prescription drug use generally increases with age.[25,26] A study assessing the 
importance of demographics in the selection of antihypertensives concluded that Ca-
channel blockers were more effective in patients over 60 years of age.[27] Nichol et al. in 
their study of factors associated with antihypertensive prescribing found that elderly 
patients (>65 years) were 78 % more likely and patients between the ages of 40 and 65 
years were nearly 50 % more likely to receive an antihypertensive than those younger 
than 40 years.[28] 
Younger members were associated with high utilization of antidepressants and beta-
blockers. This was somewhat surprising, as increasing age has been reported to be 
associated with a higher rate of depressive symptoms.[29] The results for beta-blockers 
may be explained in part by results of previous studies that show beta-blockers to be 
more effective in younger patients than elderly patients.[30] 
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Gender: 
Males were higher utilizers than females for all drug categories except for lipotropics and 
antidepressants. The results contradict the findings of a study that show females use more 
types of medications and use them to a greater extent than males do.[31] 
The utilization of H2-blockers is consistent with results of a study examining the 
prescribing of antacids and ulcer-healing drugs in primary care in the north of England. 
This study found that prescribing rates of H2-blockers were higher in males than in 
females. The disparity between the genders was attributable to males being prescribed 
H2-blockers for the treatment of ulcers.[16] 
Higher utilization of beta-blockers may be explained by results of previous studies. 
Fewer data are available, but beta-blockers have shown to be less effective in females 
than males.[27] Akoki et al. found that beta-blockers were one of the few drug categories 
which were clearly prescribed more often for males.[32] 
Many studies have shown that females were more likely than males to receive 
prescriptions for antidepressants.[33,34,35] Rosholm et al., in their study of outpatient 
utilization of antidepressants using a prescription database, found that women constituted 
a disproportionately large percentage of antidepressants users.[36] High utilization of 
lipotropics among females was not found in the literature and, therefore, needs further 
research. 
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( Location: 
Of all the states evaluated, members residing in Tennessee were the lowest utilizers of 
phannaceuticals in all six therapeutic categories. These results may be explained by 
location characteristics. Te1messee is well known for TennCare, the health care system 
refonn plan implemented in Tennessee on January 1, 1994. The program was developed 
with the dual objectives of controlling rapidly rising costs of the state's Medicaid 
program and extending health insurance coverage to Tennesseans who did not have 
access to employer-sponsored or other government-sponsored health insurance.[37] More 
than a quarter of the total population of Tennessee is currently enrolled in Te1mCare and 
the program has been successful in controlling costs in the Medicaid program. The state 
claims that in the first 18 months, TennCare saved an estimated $1.6 billion in state and 
federal funds based on the expected growth rate in conventional Medicaid expenditures. 
[37] MIM Health Plans, Inc. (TennCare's primary PBM) provides prescription benefit 
services for about 80 percent of Tennessee's Medicaid prescriptions. MIM Health 
Plans's strong presence in the Tenn Care Program along with the provision of pharmacy 
benefits for commercial clients in Tennessee may be related to what known as "spillover 
effect" . The spillover concept arises from the application of the transfer of learning 
theory to health care providers. That is, spillover occurs when a health care provider's 
behavior transfers from one segment of patient population to another. Techniques utilized 
to control utilization in the TennCare program include a highly managed formulary, 
extensive prior authorization and medical necessity protocols and dispensing limitations. 
These efforts have substantially altered provider prescribing patterns for TennCare 
enrollees. The prescribing habits of physicians that affect the Tenn Care population may 
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( be transfe1Ted to the Tennessee commercial population. Cost consciousness of phannacy 
providers in Tennessee and the staff at the PBM towards TennCare might have resulted in 
changes in their professional behavior. These changes might have benefited the 
commercial population administered by the PBM in Tennessee. 
The transfer of learning from Medicaid to non-Medicaid sector has already been shown 
in the Iowa Capitation Study. The results demonstrated "spill over" of generic 
substitution habits from Medicaid to non-Medicaid prescriptions. The study concluded 
that non-Medicaid patients benefited from pharmacists' cost-containment attitudes 
towards the Medicaid drug program.[38] 
Place of Employment: 
Members employed in art, trade & transport, primary industries and social sciences were 
the highest utilizers of cardiovascular drugs. This high utilization may be explained by 
high morbidity, prevalence, and mortality rates for cardiovascular disease among workers 
in the transportation industry.[39] This industry has been known for its low level of 
physical activity, irregular work schedules and high level of psychological stress. 
Members employed in sales & services were the lowest utilizers of antidepressants. This 
is contradictory to the results of a study that assessed crude prevalence rates for major 
depression. The study demonstrated that people employed in sales had high prevalence 
rates of depression. [ 40] 
26 
Members employed in art, trade & transport, primary industries and social sciences were 
the highest utilizers of beta-blockers. Beta-blockers are widely used in post myocardial 
infarction. The only research that was found to support or refute these results was a case-
referent study estimating the relative risk of myocardial infarction which found increased 
incidence for male employed in transport work. [ 41] 
Alsted in 1942 showed a higher incidence of peptic ulcer in medical doctors and other 
persons considered as "higher office workers".[ 42] From the results of this study one 
might expect high utilization of H2-blockers for members employed in health care. 
However, this study showed that health care employees were the lowest utilizers of H2-
blockers. High utilization ofH2-blockers among members employed in manufacturing 
may be explained by characteristics of their occupation. Studies have found that persons 
working in a hectic and irregular environment may be particularly disposed to peptic 
ulcer disease. [ 43] 
CONCLUSION: 
The primary objective of this study was to compare the variance in cost of 
pharmaceuticals that is explained by demographic variables with the variance that is 
explained by plan characteristics within various therapeutic categories using prescription 
claims data. The secondary objective was to examine whether there were differences in 
utilization among various demographic variables after controlling for appropriate 
covariates. 
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( Information for six drug categories was extracted from claims data using database 
management software. Statistical analyses utili zing multiple regression and analysis of 
covariance were carried out. Two sets of multiple regression analyses were conducted, 
one using demographic variables and the other using plan characteristics. Plan 
characteristics out-performed demographic variables sixteen-fold (4% vs. 64%) for all 
drug categories combined in explaining variance in cost of phamrnceuticals among plan 
enrollees. While significant differences in utilization were found among the various 
demographic variables (e.g. age, gender), continuous variables such as number of days 
supplied, quantity dispensed, number of days eligible, average wholesale price and co-
payment amount were found to be much more powerful predictors. 
The results obtained in this study have practical significance in the determination of 
capitation rates when the utilization history of prospective members is not available. In 
this situation, pharmacy benefit managers may have to set capitation rates based solely on 
eligibility data. Furthermore, if utilization data are available, there is a temptation to 
manipulate these data to influence capitation rates. In this scenario, enrolling the 
members initially under a FFS arrangement is a viable option. Data collected under a 
FFS arrangement may then be used to set capitation rates . 
In addition to highlighting the importance of utilization history in setting capitation rates 
for new enrollees, the study results have other ramifications. Pharmacy benefit managers 
contract with commercial clients to provide pharmacy benefits to their employees 
irrespective of their occupation. Significant differences in utili zation among the members 
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f based on place of employment may be a relevant finding for a pharmacy benefit 
manager. The implications of these findings suggest that benefit managers should 
consider differentiating capitation rates according to their clients' business. Finally, the 
data from this study indicated that commercial members in the State of Tennessee had the 
lowest level of drug utilization among all states evaluated. The unique dynamics of the 
Te1messee marketplace suggests that a "spillover effect" may exist due to transfer of 
learning from the Medicaid to the commercial population. 
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( TABLE: 1 CHARACTERISTICS OF ENROLLEES IN A PRIVATE THIRD-PARTY 
PRESCRIPTION PROGRAM:• 
MEMBERAGEt 
1-5 
6-20 
21-40 
41-64 
>64 
Mean 
MEMBER GENDER; 
FEMALE 
MALE 
PLACE OF EMPLOYMENT OF PRIMARY CARDHOLDER 
MANAGEMENT 
MAl\TUF ACTURING 
CONTRACTORS 
COMMERCE 
HEALTH 
SOCIAL SCIENCES, LA WYERS AND EDU CA TORS 
ART 
SALES AND SERVICES 
TRADE AND TRANSPORT 
PRIMARY INDUSTRIES 
*:As of December 31, 1996 
t: 323 missing age records 
t: 86 missing gender records 
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#OF PARTICIPANTS(%) 
(N= 64815) 
5666 (8.8) 
13947 (21.6) 
23739 (36.8) 
18788 (29.1) 
2352 (3.6) 
31.5 
34145 (52.8) 
30584 (47.2) 
#OF PARTICIPANTS(%) 
(N=29211) 
1236 (4.2) 
3018 (10.3) 
1374 (4.7) 
2043 (7.0) 
11634 (39.8) 
2579 (8.8) 
671 (2.3) 
5156 (17.7) 
682 (2.3) 
818 (2.8) 
VJ 
TABLE: 2 MULTIPLE REGRESSION MODEL OF COST OF PHARMACEUTICALS FOR VARIO US DRUG CATEGORIES. 
REGRESSION COEFFICIENTS (STANDARD ERROR) FOR COST OF PHARMACEUTICALS BY MEMBER DEMOGRAPHICS: 
VARIABLE 
INTERCEPT 
MEMBER AGE 
MEMBER GENDER 
MEMBER LOCATION 
PLACE OF EMPLOYMENT 
MANUFACTURING/OTHER 
HEAL TH/OTHER 
SALES & SERVICES/OTHER 
CONTRACTORS/OTHER 
COMMERCE/OTHER 
MANAGEMENT/OTHER 
N 
F 
R2 
ADJ.R2 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6: ANTIDEPRESSANTS 
1 
-
0.0813 
(0.0003) 
0.0603 
(0.0085) 
-0.3294 
(0.0116) 
0.0748 
(0.0145) 
-0.0375T 
(0 .0120) 
-0.03 l 5T 
(0.0164) 
0.0548 
(0.0195) 
-
-
6763 
150.87 
0.1352 
0.1343 
DRUG CATEGORY 
2 3 4 5 6 7 
- - - - - -
0.0769 0.0855 -0.0323T 0.1288 -0.0736 0.0660 
(0 .0006) (0.0003) (0.0008) (0.0004) (0.0005) (0.0003) 
-0.0623 0.0159 0.0445 0.0104 -0.0297 0.0073 
(0.0134) (0.0089) (0.0215) (0 .0124) (0 .0170) (0.0070) 
-0.3464 -0.2774 -0.2669 -0.3351 -0.0846 -0.2444 
(0.0162) . (0.0127) (0.0259) (0.0170) (0.0244) (0.0092) 
0.0409T -0.0044 -0.0113 0.0472 -0.0379 0.02061 
(0.0221) (0.0160) (0.0393) (0.0232) (0.0290) (0.0121) 
-0.0399 -0.1089~ -0.2220~ 0.0017 0.0273 -0.1177 
(0.0182) (0.0127) (0.0310) (0.0182) (0.0217) (0.0098) 
-0.0455T -0 . 1004~ -0.05241 -0.0021 -0.0253T -0.0742 
(0.0232) (0.0167) (0.0381) (0.0247) (0.0323) (0.0128) 
- - - - - -
0.0121 - - - 0.0435 -
(0.0278) (0.319) 
- 0.03651 -0.0417 0.0900 - -0.0020 
(0.0193) (0.0455) (0.0271) (0 .0157) 
3462 5783 3631 4297 8690 19642 
76.45 93.43 61.30 110.47 21.47 236.80 
0.1341 0.1017 0.1059 0.1390 0.0170 0.0778 
0.1324 0.1006 0.1042 0.1377 0.0162 0.0775 
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3,4) 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS (5,6) 
9: COMBINING ALL SIX DRUG CATEGORIES 
8 9 
- -
0.0126 0.0135T 
(0.0003) (0.0002) 
0.0241 0.0128T 
(0.0116) (0.0062) 
-0.1582 -0.1947 
(0 .0166) (0.0086) 
-0.0287 0.024ST 
(0.0206) (0.0167) 
-0.0075 -0.0103 
(0.0155) (0.0153) 
-0.0275 -0.0204T 
(0.0225) (0.0173) 
- 0.0408 
(0.0196) 
0.0023 0.0235 
(0.0241) (0.0188) 
- 0.0218 
(0.0189) 
13488 33131 
53.11 151.46 
0.0268 0.0395 
0.0263 0.0393 
*:significant at 0.001 
t: significant at 0.05 
VJ 
N 
TABLE: 3 MULTI COLLINEARITY DIAGNOSTIC 
VARIAN CE INFLATION FACTOR OF INDEPENDENT VARIABLES FOR MULTIPLE REGRESSION MODELS: 
VARIABLE 
MEMBER AGE 
MEMBER GENDER 
MEMBER LOCATION 
PLACE OF EMPLOYMENT 
MANUFACTURING/OTHER 
HEALTH/OTHER 
SALES & SERVICES/OTHER 
CONTRACTORS/OTHER 
COMMERCE/OTHER 
MANAGEMENT/OTHER 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
1 
1.0937 
1.0300 
1.0408 
1.6777 
2.0730 
1.5511 
1.3699 
-
-
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3,4) 
2 
1.1011 
1.0502 
1.0469 
1.5836 
1.9048 
1.5825 
-
1.3219 
-
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS (5,6) 
9: COMBINING ALL SIX DRUG CATEGORIES 
DRUG CATEGORY 
3 4 5 6 
1.0963 1.0451 1.0294 1.0170 
1.0302 1.0266 1.0182 1.0049 
1.0860 1.0440 1.0337 1.0317 
1.6237 1.6583 1.6838 1.6047 
2.0732 2.1704 2.2207 2.1431 
1.6218 1.7368 1.5850 1.4388 
- - - -
- - - 1.4719 
1.3665 1.3915 1.4460 -
7 8 9 
1.0608 1.0275 1.0760 
1.0206 1.0130 1.0182 
1.0529 1.0324 1.0545 
1.6181 1.5889 3.6775 
1.9968 2.0744 6.3104 
1.5720 1.4586 3.3051 
- - 2.2556 
- 1.3913 2.3724 
1.3054 - 2.3790 
VJ 
VJ 
TABLE: 4 MULTIPLE REGRESSION MODEL OF COST OF PHARMACEUTICALS FOR VARIO US DRUG CATEGORIES. 
REGRESSION COEFFICIENTS (STANDARD ERROR) FOR COST OF PHARMACEUTICALS BY PLAN CHARACTERISTICS: 
VARIABLE 
INTERCEPT 
# OF DAYS ELIGIBLE 
# OF MEMBERS ELIGIBLE 
A VERA GE WHOLESALE 
PRICE 
OUT OF POCKET 
EXPENSE 
# OF DAYS SUPPLY 
QUANTITY DISPENSED 
N 
F 
R2 
ADJ.R2 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
4: BET A-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
1 2 
- -
-0.4589 -0.3722 
(0.0000) (0.0000) 
0.0228 0.0557 
(0.0033) (0.0054) 
0 . 6216~ 0 . 6764~ 
(0.0043) (0.0042) 
0.0018 0 . 0493~ 
(0.0097) (0.0165) 
0.1324~ 0.2761~ 
(0.0170) (0.0238) 
0.4721 0.2101 
(0.0144) (0.0186) 
6519 3343 
3800.21 1752.17 
0.7778 0.7591 
0.7776 0.7586 
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3,4) 
3 
-
-0.4697 
(0.0000) 
0.0629 
(0.0036) 
. 0 . 3327~ 
(0.0305) 
-0.1721 
(0.0105) 
0.0306~ 
(0.0001) 
0.6542 
(0.0147) 
5651 
2993.54 
0.7609 
0.7606 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS (5,6) 
9: COMBINING ALL SIX DRUG CATEGORIES 
DRUG CATEGORY 
4 5 
- -
-0.2053 -0.3726 
(0.0001) (0.0000) 
-0.0452 0.0236T 
(0.0160) (0.0062) 
0.3291 0.3940 
(0.0390) (0.0073) 
0.2076 0.1695 
(0.0412) (0.0170) 
0.1210~ 0.0535~ 
(0.0091) (0.0043) 
0.2673 0.5520 
(0.0557) (0.0271) 
3184 4462 
278.68 1251.00 
0.3448 0.6275 
0.3435 0.6270 
*: significant at 0.001 
t: significant at 0.05 
6 
-
-0.2547 
(0.0000) 
0.0146 
(0.0040) 
0.9571 
(0.0089) 
-0.0258 
(0.0160) 
-0.0143 
(0.0028) 
0.4293 
(0.0145) 
7809 
9361.93 
0.8780 
0.8779 
7 8 
- -
-0.3105 -0.2670 
(0.0000) (0.0000) 
0.0042 0.0185 
(0.0035) (0.0045) 
0.6376 0.7 164 
(0.0083) (0.0092) 
0.0824 0.1171 
(0.0097) (0.0150) 
0.0696 -0.0116 
(0.0023) (0.0029) 
0.3792 0.4765 
(0.0141) (0.0157) 
18700 12372 
5058.47 5032.43 
0.6188 0.7094 
0.6187 0.7093 
-, 
9 
-
-0.2785 
(0.0000) 
0.0059 
(0.0029) 
0.6405 
(0.0027) 
0.1284 
(0 .0084) 
0.0453 
(0.0018) 
0.3937 
(0.0105) 
31073 
9109.77 
0.6376 
0.6375 
w 
.j:>. 
TABLE: 5 MULTI COLLINEARITY DIAGNOSTIC 
VARIANCE INFLATION FACTOR OF INDEPENDENT VARIABLES FOR MULTIPLE REGRESSION MODELS: 
VARIABLE 
INTERCEPT 
#OF DAYS ELIGIBLE 
# OF MEMBERS ELIGIBLE 
A VERA GE WHOLESALE PRICE 
OUT OF POCKET EXPENSE 
#OF DAYS SUPPLY 
QUANTITY DISPENSED 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
1 
-
1.0380 
1.0344 
1.1336 
1.0677 
1.9464 
2.0193 
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3,4) 
2 
-
1.0297 
1.0632 
1.3307 
1.0724 
1.16673 
1.7769 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS (5,6) 
9: COMBINING ALL SIX DRUG CATEGORIES 
DRUG CATEGORY 
3 4 5 6 
- - - -
1.0704 1.0646 1.0669 1.0974 
1.0648 1.1546 1.0971 1.1068 
1.0058 1.1064 1.24 71 2.0345 
1.0347 1.1636 1.0910 1.8163 
1.8436 1.9198 2.4860 1.4767 
1.8077 1.8827 2.4676 1.6724 
------... 
7 8 9 
- - -
1.0471 1.0851 1.0588 
1.0622 1.1008 1.0713 
1.1584 1.5358 1.1852 
1.0775 1.3917 1.1368 
1.9350 1.6233 1.6813 
1.9749 1.7419 1.7239 
w 
Ul 
,---._ 
~ 
TABLE: 6 MULTIPLE REGRESSION MODEL OF COST OF PHARMACEUTICALS FOR VARIOUS DRUG CATEGORIES. 
REGRESSION COEFFICIENTS (STANDARD ERROR) FOR COST OF PHARMACEUTICALS BY MEMBER DEMOGRAPHICS AND PLAN 
CHARACTERISTICS: 
VARIABLE 
1 2 
INTERCEPT - -
MEMBERAGE 0.0423 (0 .0001) 0.0052 (0 .0003) 
MEMBER GENDER -0.01371 (0 .0043) -0.0639 (0.0072) 
MEMBER LOCATION 0.0574 (0 .0081) -0.0019 (0.0120) 
MANUFACTURING -0.0377 (0 .0080) -0 . 0465~ (0 .0125) 
HEALTH -0.1172 (0.0074) -0.0737 (0.0115) 
SALES & SERVICES -0.0023 (0 .0088) -0.0194 (0 .0133) 
CONTRACTORS -0.0606 (0 .0109) -
MANAGEMENT - -
COMMERCE - -0.02011 (0.0 I 53) 
# OF DAYS ELIGIBLE -0.4538 (0.0000) -0.3647 (0 .0000) 
# OFMEMBERS 0.0793 (0.0041) 0 . 0771~ (0.0067) 
ELIGIBLE 
AVERAGE 0.6149 (0.0043) 0.6739 (0.0043) 
WHOLESALE PRICE 
OUT OF POCKET 0.0281 (0.0101) 0.0569 (0.0172) 
EXPENSE 
# OF DAYS SUPPLY 0.1613 (0.0191) 0.2726 (0.0268) 
QUANTITY 0.4906 (0.0145) 0.2207 (0.0195) 
DISPENSED 
N 6477 3328 
F 1842.60 828 .99 
R2 0.7875 0.7648 
ADJ.R2 0.7871 0.7638 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
*: significant at 0.001 
t: significant at 0.05 
3: ACE INHIBITORS 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
DRUG CATEGORY 
3 4 5 6 
- - - -
0.0002 (0.0002) 0.0064 (0 .008) 0.0493 (0.0002) 0.0039 (0.0002) 
0.0081 (0.0046) -0.0054 (0 .0203) -0.0241 (0.0075) -0.0112 (0.0063) 
0.0613 (0.0099) 0.0209 (0.0384) 0.0023 (0 .0141) 0.0236 (0.0128) 
0.0715 (0.0085) 0.0084 (0.0396) 0.0810 (0.0142) -0.0001 (0.0113) 
0.0563 (0.0076) -0.1285 (0 .0371) -0.0230(0.0127) -0.0123 (0.0098) 
0.0468 (0.0092) 0.0651 (0 .0419) 0.0730 (0.0153) -0.0021 (0.0132) 
- - -
-
0.0308 (0.0122) 0.0652 (0 .0563) 0.2432 (0 .01 79) -
- - - -0.0214 (0 .0122) 
-0.4778 (0.0000) -0.1939 (0 .0001) -0.3810 (0.0000) -0.2556 (0 .0000) 
0.0492~ (0.0043) 0.04 711 (0.0193) 0.1148 (0.0070) 0.0134 (0.0047) 
0.3326 (0.0314) 0.3202 (0.0394) 0.35861 (0.0069) 0.9553 (0.0093) 
-0.1609 (0 .0139) 0.2103 (0 .0429) 0.2658 (0.0176) -0.0223 (0 .0166) 
0.0723 (0.0002) 0.1462 (0 .0120) 0.0494 (0 .0048) -0.0007 (0.0036) 
0.6597 (0.0147) 0.2927 (0.0555) 0.5548 (0.0253) 0.4346 (0.0146) 
5617 3167 4421 7766 
1408.23 145 .33 745 .37 4314.64~ 
0.7656 0.3746 0.6873 0.8786 
0.7651 0.3720 0.6864 0.8784 
w 
°' 
--.. 
TABLE: 7 MULTIPLE REGRESSION MODEL OF COST OF PHARMACEUTICALS FOR COMBINED DRUG CATEGORIES. 
REGRESSION COEFFICIENTS (STANDARD ERROR) FOR COST OF PHARMACEUTICALS BY MEMBER DEMOGRAPHICS AND PLAN 
CHARACTERISTICS: 
VARIABLE DRUG CATEGORY 
7 8 
INTERCEPT - -
MEMBERAGE 0.0091 (0.0002) 0.0075 (0.0002) 
MEMBER GENDER -0.0042 (0.0045) -0.0085 (0.0064) 
MEMBER LOCATION 0.0723 (0.0089) 0 . 0298~ (0.0127) 
MANUFACTURING 0.0155 (0.0081) -0.0673 (0.01 17) 
HEALTH -0.0539 (0.0073) . -0.1113 (0.0102) 
SALES & SERVICES 0.0409 (0.0088) -0.0381 (0.0135) 
CONTRACTORS - -
MANAGEMENT 0.1199 (0.0118) -
COMMERCE - -0.0795 (0.0135) 
# OF DAYS ELIGIBLE -0.3051 (0.0000) -0.2608 (0.0000) 
# OF MEMBERS ELIGIBLE 0.0568 (0.0042) 0 . 0378~ (0.0053) 
A VERA GE WHOLESALE PRICE 0.6165 (0.0083) 0.7010 (0.0094) 
OUT OF POCKET EXPENSE 0.1506 (0.0108) 0.1378 (0.0154) 
# OF DAYS SUPPLY 0. 1 246~ (0.0028) 0.0087 (0.0037) 
QUANTITY DISPENSED 0.3950 (0.0139) 0.4763 (0.0156) 
N 18592 12288 
F 2520.71 2381.87 
R2 0.6382 0.7161 
ADJ.R2 0.6379 0.7158 
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3 ,4) 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS (5 ,6) 
9: COMBINING ALL SIX DRUG CATEGORIES 
*:significant at 0.001 
t : significant at 0.05 
9 
-
0.0230 (0.0001) 
0.0008 (0.0038) 
0.0635 (0.0075) 
-0.0261 (0.0107) 
-0.0923 (0.0102) 
0.0060(0.0110) 
-0.0270 (0.0129) 
0.12 18 (0.0 125) 
-0.0366 (0.0116) 
-0.2801 (0.0000) 
0.0653 (0.0035) 
0.6153 (0.0027) 
0.2044 (0.0092) 
0.0878~ (0.0022) 
0.4044 (0.0103) 
30881 
4005.60 
0.6606 
0.6605 
---,_ 
w 
-....) 
TABLE: 8 MULTICOLLINEARITY DIAGNOSTIC 
VARIAN CE INFLATION FACTOR OF INDEPENDENT VARIABLES FOR MULTIPLE REGRESSION MODELS: 
VARIABLE 
INTERCEPT 
MEMBER AGE 
MEMBER GENDER 
MEMBER LOCATION 
MANUFACTURING/OTHER 
HEAL TH/OTHER 
SALES&SERVICES/OTHER 
CONTRACTORS/OTHER 
MANAGEMENT/OTHER 
COMMERCE/OTHER 
# OF DAYS ELIGIBLE 
# OF MEMBERS ELIGIBLE 
A VERA GE WHOLESALE PRICE 
OUT OF POCKET EXPENSE 
# OF DAYS SUPPLY 
QUANTITY DISPENSED 
l : Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
l 
-
1.1504 
1.0464 
2.0564 
2.0953 
3.1012 
1.6409 
1.6130 
-
-
1.1655 
1.6290 
1.1693 
1.2009 
2.5431 
2.1329 
7: COMBINING CARDIOVASCULAR DRUGS (1 ,2,3,4) 
2 
-
1.1758 
1.0673 
2.0214 
1..8443 
2.6738 
1.8521 
-
-
1.4413 
1.0927 
1.6547 
1.3939 
1.1854 
2.1614 
1.9821 
8: COMBINING ID-BLOCKERS AND ANTI DEPRESSANTS (5,6) 
9: COMBINING ALL SIX DRUG CATEGORIES 
DRUG CATEGORY 
3 4 5 6 7 
- - - - -
1.1452 1.1518 1.1380 1.0562 1.1082 
1.0361 1.0444 1.0253 1.0159 1.0258 
2.4930 2.6712 2.0427 2.0279 2.3694 
1.7580 2.1368 1.8199 1.9799 1.8399 
2.7950 3.5233 2.9847 3.2179 2.7506 
1.7823 2.1006 1.6224 1.5428 1.7100 
- - - - -
2.0963 1.5359 1.7186 - 1.6352 
- - - 1.7421 -
1.1732 1.1513 1.1650 1.1495 1.1341 
1.5934 1.7396 1.6759 1.5223 1.5849 
1.0754 1.1520 1.2970 2.1712 1,2059 
1.8220 1.3076 1.3648 1.9625 1.3815 
3.0074 3.4301 3.6240 2.4261 3.0238 
1.8398 1.9083 2.5243 1.6970 2.0006 
,..--....., 
8 9 
- -
1.0762 1.1367 
1.0297 1.0278 
2.0736 2.2378 
1.8340 4.2755 
2.9503 7.6687 
1.5703 3.3600 
- 2.2596 
- 2.5854 
1.5504 2.5765 
1.1423 1.1566 
1.5628 1.6493 
1.6086 1.2329 
1.5067 1.4262 
2.6047 2.7301 
1.7706 1.7505 
w 
00 
TABLE: 9 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY MEMBER AGE FOR VARIO US DRUG CATEGORIES: 
ANOVA 
F(p) 
Rl 
ANCOVA (COVARIATE) 
#OF l\tEMBERS ELIGll3LE 
F(p) 
R-
AVERAGE WHOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R-
LS MEANS 
1-5 
6-20 
21-40 
41-64 
>64 
I: Ca CHANNEL BLOCKERS 
Z: LIPOTROPJCS 
3: ACE INHIBITORS 
1 2 
38.13 7.95 
(0.0001) (0.0001) 
0.0165 0.0090 
30.25 9.22 
(0.0001) (0.0001) 
0.0175 0.0132 
1151.32 945 .07 
(0.0001) (0.0001) 
0.4584 0.6203 
- -
0.0901 0.1288 
0.0876 0.1260 
0.0932 0.1274 
0.1042 0.1355 
4: BET A-BLOCKERS 
5: HZ-BLOCKERS 
6: ANTI DEPRESSANTS 
3 
27.77 
(0.0001) 
0.0141 
20.71 
(0.0001) 
0.0142 
492.97 
(0.0001) 
0.2976 
-
0.0466 
0.0647 
0.0645 
0.0745 
DRUG CATEGORY 
4 5 6 7 8 
16.61 35.80 30.39 43 .85 10.94 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
0.0134 0.0287 0.0137 0.0088 0.0032 
24.20 30.06 27.62 38.71 9.97 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
0.0260 0.0304 0.0157 0.0097 0.0036 
148.17 320.56 2674.27 2469.39 2164.83 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
0.1689 0.2845 0.6506 0.4286 0.4890 
- 0.1429 - - 0.1000 
0.0336 0.1737 0.0657 0.0638 0.1058 
0.0159 0.1427 0.1014 0.0624 0.0974 
0.0261 0.1521 0.0805 0.0700 0.1041 
0.0219 0.2224 0.0519 0.0728 0.1391 
7: COMBINING CARDIOVASCULAR DRUGS ( l ,Z,3,4) 
8: COMBINING HZ-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORJES 
9 
6.91 
(0.0001) 
0.0008 
8.77 
(0.0001) 
0.0013 
4481.56 
(0.0001) 
0.4465 
0.0785 
0.0809 
0.0782 
0.0821 
0.0899 
....., 
\0 
TABLE: 10 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY MEMBER GENDER FOR VARIO US DRUG 
CATEGORlES: 
ANOVA 
F(p) 
R' 
ANCOVA (COVARIATE) 
MEMBER AGE 
F(p) 
R-
#OF MEMBERS ELIGIBLE 
F(p) 
R' 
AVERAGE WHOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R' 
LSMEANS 
FEMALE 
MALE 
I: Ca CHANNEL BLOCKERS 
Z: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 
34.05 18.06 
(0.0001) (0.0001) 
0.0049 0.0051 
75.30 31.16 
(0.0001) (0.0001) 
0.0217 0.0176 
16.60 11.96 
(0.0001) (0.0001) 
0.0049 0.0069 
1893.35 1887.08 
(0.0001) (0.0001) 
0.4559 0.6205 
0.0919 0.1335 
0.0973 0.1245 
4: BETA-BLOCKERS 
5: HZ-BLOCKERS 
6: ANTI DEPRESSANTS 
3 
0.16 
(0.6937) 
0.0000 
60.00 
(0.0001) 
0.0202 
1.15 
(0.3160) 
0.0004 
802.65 
(0.0001) 
0.2936 
0.0648 
0.0665 
DRUG CATEGORY 
4 5 6 7 8 
4.26 4.13 8.85 5.90 10.15 
(0.0390) (0.0422) (0.0029) (0.0152) (0.0014) 
0.0011 0.0008 0.0010 0.0002 0.0007 
2.13 58.47 23.39 100.36 11.31 
(0.1184) (0.0001) (0.0001) (0.0001) (0.0001) 
0.0011 0.0236 0.0053 0.0100 0.0016 
20.58 2.71 7.63 18.80 8.75 
(0.0001) (0.0668) (0.0005) (0.0001) (0.0002) 
0.0112 0.0011 0.0017 0.0019 0.0013 
227.09 584.34 5253.35 4897.30 4160.03 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
0.1576 0.2662 0.6473 0.4273 0.4796 
0.0230 0.1571 0.0867 0.0689 0.1015 
0.0247 0.1612 0.0784 0.0701 0.1164 
7: COMBINING CARDIOVASCULAR DRUGS (1 ,Z,3,4) 
8: COMBINING HZ-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
9 
0.56 
(0.4541) 
0.0000 
5.60 
(0.0037) 
0.0003 
9.17 
(0.0001) 
0.0005 
8851.10 
(0.0001) 
0.4441 
0.0810 
0.0848 
.;:. 
0 
TABLE: 11 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY MEMBER LOCATION FOR VARIOUS DRUG 
CATEGORIES: 
ANOVA 
F(p) 
R" 
ANCOVA (COVARIATE) 
MEMBER AGE 
F(p) 
R-
#OF MEMBERS ELIGIBLE 
F(p) 
R-
AVERAGE WHOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R-
LS MEANS 
OTHER 
TENNESSEE 
I: Ca CHANNEL BLOCKERS 
Z: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 
841.03 468.03 
(0.0001) (0.0001) 
0.1102 0.1187 
447 .95 245.34 
(0.0001) (0.0001) 
0.1166 0.1238 
421.30 235 .29 
(0.0001) (0.0001) 
0.1110 0.1201 
1894.45 1883.16 
(0.0001 ) (0.0001) 
0.4558 0.6194 
0.1734 0.2111 
0.0838 0.1126 
4: BETA-BLOCKERS 
5: HZ-BLOCKERS 
6: ANTI DEPRESSANTS 
3 
488.25 
(0.0001) 
0.0775 
266.15 
(0.0001) 
0.0839 
242.39 
(0.0001) 
0.0778 
808.52 
(0.0001) 
0.2947 
0.1086 
0.0599 
DRUG CATEGORY 
4 5 6 7 
251.33 621.87 43.99 1229 .91 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.0646 0.1146 0.0050 0.0587 
128.31 357.59 50.93 653.30 
(0.0001) (0.000 1) (0.0001) (0.0001) 
0.0659 0.1296 0.0115 0.0621 
154.79 318.41 25.36 637 .8 1 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.0790 0.1183 0.0058 0.0612 
240.93 591 .26 5272.03 4912.06 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.1659 0.2697 0.6477 0.4278 
0.0477 0.3402 0.1559 0.1193 
0.0198 0.1388 0.0802 0.0618 
7: COMBINING CARDIOVASCULAR DRUGS (I,Z,3,4) 
8: COMBINING HZ-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORJES 
8 9 
347.91 1216.82 
(0.0001) (0.0001) 
0.0250 0.0353 
174.47 612.00 
(0.0001) (0.0001) 
0.0251 0.0355 
181.09 621.59 
(0.0001) (0.0001) 
0.0263 0.0363 
4176.50 8875 .28 
(0.0001) (0.0001) 
0.4809 0.4448 
0.2121 0.1460 
0.0960 0.0743 
~ 
-
TABLE: 12 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY PLACE OF EMPLOYMENT FOR VARIOUS DRUG 
CATEGORIES: 
ANOVA 
F(p) 
R-
ANCOVA (COVARlATE) 
MEMBER AGE 
F(p) 
RL 
#OF MEMBERS ELIGIBLE 
F(p) 
RL 
AVERAGE WHOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R-
LS MEANS 
MANAGEMENT 
MANUFACTURING 
HEALTH 
SALES & SERVICES 
COMMERCE 
CONTRACTORS 
OTHERS 
I: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 
14.4 3.01 
(0.0001) (0.0173) 
0.0133 0.0053 
29.57 10.15 
(0.0001) (0.0001) 
0.0334 0.0223 
11.89 2.21 
(0.0001) (0.0506) 
0.0138 0.0049 
608.03 617.01 
(0.0001) (0.0001) 
0.4609 0.6251 
- -
0.0944 0.1313 
0.0812 0.1197 
0.0995 0.1194 
- 0.1336 
0.1250 -
0.0938 0.1342 
4: BETA-BLOCKERS 
5: HZ-BLOCKERS 
3 
10.52 
(0.0001) 
0.0105 
28.00 
(0.0001) 
0.0342 
8.71 
(0.0001) 
0.0109 
281.24 
(0.0001) 
0.2992 
0.0736 
0.0654 
0.0604 
0.0621 
-
-
0.0725 
6: ANTI DEPRESSANTS 
DRUG CATEGORY 
4 5 6 7 
23.19 3.46 7.56 34.64 
(0.0001) (0.0079) (0.0001) (0.0001) 
0.0388 0.0041 0.0051 0.0105 
18.55 17.46 14.56 60.77 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.0389 0.0257 0.0123 0.0228 
18.55 3.52 6.94 28.63 
(0.0001) (0.0036) (0.0001) (0.0001) 
0.0392 0.0053 0.0059 0.0109 
103.04 197.29 1675.61 1625.96 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.2125 0.2637 0.6373 0.4286 
0.0264 0.1904 - 0.0737 
0.0190 0.1923 0.0914 0.0692 
0.0159 0.1493 0.0858 0.0590 
0.0361 0.1703 0.0857 0.0730 
- - 0.0884 -
- - - -
0.0402 0.1563 0.1226 0.0835 
7: COMBINING CARDIOVASCULAR DRUGS (1 ,Z,3 ,4) 
8: COMBINING HZ-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
8 9 
0.17 8.42 
(0.9531) (0.0001) 
0.0000 0.0022 
0.55 7.95 
(0.7404) (0.0001) 
0.0003 0.0025 
0.29 7.59 
(0.9205) (0.0001) 
0.0001 0.0024 
1366.68 2248.52 
(0.0001) (0.0001) 
0.4734 0.4484 
- 0.0941 
0.1144 0.0834 
0.1047 0.0756 
0.1186 0.0877 
0.0993 0.0861 
- 0.1135 
0.1338 0.0929 
~ 
+:> 
N 
'• 
TABLE: 13 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY PLACE OF EMPLOYMENT AND MEMBER GENDER 
FOR VARIO US DRUG CATEGORIES: 
ANOVA 
F(p ) 
R· 
ANCOVA (COVARIATE) 
MEMBER AGE 
F(p) 
R· 
# OF MEMBERS ELIGIBLE 
F(p) 
R· 
AVERAGE WllOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R' 
LSMEANS 
MANAGEMENT-F 
MANAGEMENT- Mr 
MANUF ACTURING- F 
MANUFACTURING-M1 
COMMERCE - FEMALE 
COMMERCE - MALE 
HEAL TH - FEMALE 
HEAL TH - MALE 
SALES & SERVICES- F~ 
SALES & SERVICES-MT 
CONTRACTORS - F 
CONTRACTORS - M1 
OTHER - FEMALE 
OTHERS - MALE 
I: Ca CHANNEL BLOCKERS 
Z: LIPOTROPICS 
3: ACE INHIBITORS 
I z 
8.9(0.0001) 3.8(0.0001) 
0.0185 0.0153 
18.8(0.000 I) 7.1 (0.000 I) 
0.04Z3 0.03 15 
8.1 (0.000 I) 3 .3(0.000 I) 
0.0189 0.0150 
339.5 35Z.5 
(0.0001) (0.0001) 
0.4674 0.6377 
- -
- -
0.1081 0.1713 
0.0881 0.1099 
- 0.1836 
- 0.1075 
0.0790 0.1195 
0.0927 O.IZ09 
0.0886 O. IZ73 
0.1073 0.1179 
0.1353 -
0.IZIZ -
0.0987 O.I ZZ6 
0.0900 0.1388 
4: BETA-BLOCKERS 
5: HZ-BLOCKERS 
6: ANTI DEPRESSANTS 
DRUG CATEGORY 
3 4 5 6 7 8 9 
6.9(0.000 I) I 4.Z(0.000 I) 8.0(0.000 I) 6.0(0.000 I) 19.6(0.0001) 7.4(0.000 I) 6.9(0.0001 ) 
0.0155 0.053Z O.OZI4 0.009Z 0.0134 0.0073 0.0040 
16.6(0.000 I) I Z.8(0.000 I) 14.1(0.0001) 8.9(0.0001) 34.Z(0.000 I) 6.8(0.000 I) 7.0(0.0001) 
0.0407 0.0533 0.04 10 0.0 153 O.OZ57 0.0075 0.0044 
6.3(0.000 I) l Z.8(0.000 I) 7 .6(0.000 I) 5.7(0.0001) I 8.Z(0.000 I) 6.8(0.000 I) 6.9(0.0001) 
0.0160 0.0535 O.OZ30 0.0098 0.0139 0.0076 0.0044 
153.5 58.3 114.5 936.0 884.0 761.9 1199.9 
(0.000 I) (0.0001) (0.000 I) (0.000 I) (0 .0001) (0.0001) (0.0001) 
0.3010 O.Zl95 O.Z766 0.6440 0.4Z90 0.4799 0.4496 
0.0699 O.OZ79 O.Z l89 - 0.0725 - 0.0888 
0.0770 O.OZ59 0.1770 - 0.0737 - 0.0973 
0.0651 0.0168 O.Z447 0.1075 0.0731 0.1340 0.0943 
0.0657 O.OZl I 0.1504 0.0758 0.0671 0.06ZO 0.0761 
- - - 0.088Z - 0.0997 0.09IZ 
- - - 0.0904 - 0.0993 0.0794 
0.0615 0.0174 0.1405 0.0813 0.0597 0.0990 0.0741 
0.0571 0.0115 0.190Z O.IZ05 0.0565 0.1548 0.0843 
0.0693 0.0349 0.1630 0.1007 0.0717 0.1150 0.0873 
0.0598 0.0366 0.1736 0.0731 0.0738 0. IZ55 0.0887 
- - - - - -
0.1018 
- - - - - -
0.1194 
0.0700 0.0458 0.1667 0.1410 0.0863 O.IZ41 O. IOZO 
0.0745 0.0373 0. 1479 O.IZ92 0.08 17 0.1445 0.0869 
7: COMBINING CARDIOVASCULAR DRUGS (1,Z,3,4) *:FEMALE 
8: COMBINING HZ-B LOCKERS AND ANTI DEPRESSANTS t : MALE 
9: COMBINING ALL SIX DRUG CATEGORIES 
.j>. 
w 
~ 
TABLE: 14 EFFECT SIZE OF INTERACTION BETWEEN DAYS SUPPLY (COVARIATE) AND GROUPING VARIABLE FOR VARIOUS DRUG 
CATEGORIES: 
GROUPING VARIABLE 
MEMBER AGE 
PLACE OF EMPLOYMENT 
LOCATION OF MEMBER 
MEMBER GENDER 
PLACE OF EMPLOYMENT AND 
MEMBER GENDER 
l: Ca CHANNEL BLOCKERS 
Z: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 
0.0023 0.0007 
0.0003 -0.0001 
0.0037 0.0011 
0.0001 0.0000 
0.0014 0.0014 
4: BET A-BLOCKERS 
5: HZ-BLOCKERS 
6:ANTIDEPRESSANTS 
DRUG CATEGORY 
3 4 5 6 7 
0.0007 0.0036 0.0095 0.0023 0.0007 
0.0038 0.0044 0.0034 0.0006 0.0010 
0.0012 -0.0001 0.0014 0.0007 0.0000 
0.0000 0.0000 -0.0001 0.0000 0.0000 
0.0036 0.0096 0.0050 0.0020 0.0019 
7: COMBINING CARDIOVASCULAR DRUGS (l,Z,3,4) 
8: COMBINING HZ-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
8 9 
0.0031 0.0017 
0.0001 0.0002 
0.0002 0.0000 
0.0000 0.0000 
0.0008 0.0004 
~ 
~ 
....... 
TABLE: 15 EFFECT SIZE OF INTERACTION BETWEEN AVERAGE WHOLESALE PRICE (COVARIATE) AND GROUPING VARIABLE FOR 
VARIOUS DRUG CATEGORIES: 
GROUPING VARIABLE 
MEMBERAGE 
PLACE OF EMPLOYMENT 
LOCATION OF MEMBER 
MEMBER GENDER 
PLACE OF EMPLOYMENT AND 
MEMBER GENDER 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 
0.0054 0.0000 
0.0032 0.0125 
0.0008 0.0032 
-0.0001 0.0009 
0.0067 0.0130 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
DRUG CATEGORY 
3 4 5 6 7 
0.0037 0.0088 0.0034 0.0024 0.0027 
0.0034 0.0156 -0.0001 0.0123 0.0036 
-0.0001 0.0000 0.0013 0.0000 0.0006 
-0.0001 0.0004 0.0002 0.0020 0.0000 
0.0079 0.0151 0.0014 0.0195 0.0043 
7: COMBINING CARDIOVASCULAR DRUGS {l,2,3,4) 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
8 9 
0.0029 0.0007 
0.0031 0.0268 
0.0000 0.0007 
0.0012 0.0006 
0.0078 0.0058 
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MANUSCRIPT II 
The Effect of Plan Characteristics on the Cost of Pharmaceuticals in a Private Third-Paiiy 
Prescription Program 
50 
( ABSTRACT: 
Objective: Using prescription claims data, the primary objective of this study was to 
evaluate whether utilization differed among various plan characteristics after controlling 
for covariates. The secondary objective was to examine the relationships among plan 
characteristics and cost of pharmaceuticals within various therapeutic categories. 
Design: Retrospective, cross-sectional study. 
Data Collection: Data for this study were obtained from 1996 prescription claims 
information for a commercial population administered by a Rhode Island-based PBM. 
Six therapeutic categories were analyzed. 
Methodology: Information on claims for six drug categories was extracted using 
database management software. Statistical analyses utilizing multiple regression and 
analysis of covariance were carried out. 
Results: Significant associations were found between plan characteristics and cost of 
pharmaceuticals. Utilization differed among various plan characteristics such as co-
payment, mode of payment, formulary status and pharmacy type after controlling for 
average wholesale price and days supply. 
Conclusion: Results obtained in this study may be helpful in understanding some of the 
factors associated with cost of pharmaceuticals. For example, the inverse relationship of 
51 
( phannaceutical cost with eligible days may be helpful in budgeting progr<l?1 costs while 
the non-significant association of pharmaceutical cost with number of members eligible 
suggests a lack of importance of group size in negotiating pharmacy benefit contracts. 
Differences in utilization among various co-payment levels suggest the effectiveness of 
different co-payment levels in promoting use of generic products. Lower utilization found 
under capitation may be encouraging to those pharmacy benefit management companies 
accepting a capitation method of reimbursement. Association of closed formularies with 
higher utilization indicates the importance of adjusting cost data for rebates before 
evaluating formulary strategies. Finally, differences in utilization between independent 
and chain pharmacies suggest the importance of careful contract negotiation. 
Key words: 
Cost of pharmaceuticals, Plan characteristics, Utilization, Confounding variables, 
Prescription claims data, PBM, Multiple regression, Analysis of covariance, Co-payment, 
Mode of payment, Formulary 
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( INTRODUCTION: 
In 1996, third-party payers processed 55% of the prescription volume and 58.5% of the 
dollar volume. [ 1] Large purchasers of phannaceutical benefits (e.g. government, 
employers) are experiencing a higher rate of inflation in their prescription program 
expenditures than seen in their medical care expenditures. [2] While product price 
increases are an issue, IMS America, a leading provider of sales management and market 
research infonnation to the phamrnceutical industry, has estimated that only 1.6% of the 
11. 7% growth in pham1aceutical dollars spent in 1996 can be attributed to manufacturer 
price increases of existing products. [3] In the past, costs of administering third-party 
prescriptions averaged only about 5% of the total prescription price and has primarily 
been for claims processing. [4] The administrative component of the prescription drug 
benefit has expanded significantly in recent years. Functions now include activities such 
as pharmacy network management, prior approval mechanisms, formulary development, 
rebate contracting, rebate administration, therapeutic alternative programs, 
pharmacoeconomic studies and disease state management programs. 
Analysts believe that increased product costs are in part due to the availability and use of 
newer and more expensive medications. Many of these products are superior to older 
formulations in terms of safety and efficacy. New products may be used for previously 
untreated or under-treated diseases. Harvard Pilgrim Health Care has projected that by 
the year 2002 drug costs will grow to 22% of total medical costs exceeding hospital 
expenditures. [5] 
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( In a recent survey of employer benefit managers and directors of employer coalitions, 
cost was ranked first among the 23 factors influencing health plan selection. [6] High 
demand among employees has led their employers to choose a carefully designed, cost-
effective pham1acy benefit that is comprehensive enough to meet their employees' 
diverse needs. More recently, corporations utilize pharmacy benefit management 
companies (PBMs) for their employees' prescription benefits. As the transition towards 
managed care continues, the standard services offered by PBMs (e.g. pharmacy networks, 
claims-processing, fommlary management) have become commonplace. This has forced 
the PBM industry to expand its product lines and create an expectation of reduced drug 
expenditures. [2] 
Phamrnceutical benefit managers have both the incentive and the ability to deliver cost 
savings to their clients. Many managed care organizations and employers have segregated 
the pharmacy benefit from the general health plan by using separate management and fee 
structures. This carve-out approach has allowed PBM managers to focus on drug costs 
independent of all related health care costs. This is achieved through various cost-
management techniques. The primary strategies include contracting with pharmacies, 
member co-payment, drug utilization review (DUR) and formularies. 
According to a study conducted in 1994, over two-thirds of all HM Os used formularies to 
help manage their prescription costs. [7] HMOs and employers choose from various 
formulary options. The design of formularies continues to evolve by becoming more 
flexible and less easily categorized as strictly open (both formulary and non-formulary 
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( drugs are covered) or closed (only fomrnlary drugs are covered). A recent survey of 
PBMs reported a definitive trend toward selective/partially closed formulary designs 
(formulary drugs and selected non-fonnulary drugs are covered). In 1996, 80% of 
surveyed PBMs described their formulary design as open with the remaining 20% evenly 
divided between closed and selective/partially closed designs. In 1997, the PBMs 
utilizing the open formulary concept underwent a noticeable shift in their forrnulary 
designs. In that year, only 50% of the forrnularies remained open, while 
selective/partially closed designs increased to 41.7%, and 8.3% remained closed. It is 
predicted that by 1999, over 80% of PBMs will have selective/partially-closed designs 
and less than 20% will have either open or closed designs. [6] 
An association exists between a well-controlled forrnulary and decreased costs. [8] Drug 
forrnularies have been implemented in a variety of health care environments with the 
objective of providing cost-effective prescription coverage by controlling drug utilization 
and expenditures. Although there have been numerous studies that document savings 
associated with hospital formularies, few studies have been conducted on ambulatory 
patients showing that forrnularies result in cost savings. An ambulatory patient drug 
forrnulary was shown to be cost effective in the 1993 study of Well Point's prescription 
claims database. [7] 
PBMs are sometimes offered capitation payment as an alternative to fee for service for a 
variety of population groups and benefit packages. In this way, the payer limits financial 
risk by paying the PBM a specified amount for each member per unit of time. The PBM 
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( must provide all of the contracted services for that fixed amount thereby assuming a 
substantial level of financial risk. To accomplish this, PBMs need to encourage new 
physician practice patterns and monitor drug utilization. With capitation payments linked 
to HMO premiums for commercial enrollees and HMO premiums having dropped in 
response to market pressure from employers, PBMs are coming under increased financial 
pressure. [9] A detailed analysis of cunent utilization data can identify the cmTent cost of 
the products/services to be capitated, allowing an educated assessment of whether a 
capitated anangement is financially viable. 
Managed health care plans are increasing consumer cost-sharing provisions in response 
to rising health care costs. Cost sharing for the prescription drug benefit is widespread 
and usually in the fonn of co-payments. Approximately 80% of all HMO members in the 
U.S. who are insured for prescription benefits have some form of prescription cost-
sharing provisions. [ 10, 6] Requiring beneficiaries to pay small dollar amounts each time 
a prescription is received theoretically inhibits unnecessary utilization, thereby containing 
the overall cost of drug benefit programs. 
Previous studies in other settings have 'shown that patients with no cost sharing 
provisions utilize more services, including prescription drugs, than those who are subject 
to cost sharing. [11] Few formal studies have researched the impact of drug co-payments 
in managed care settings. Empirical investigations of co-payments have been seriously 
limited by research design. It is important to examine the effects of co-payments on 
different therapeutic classes of drugs because their effects may vary among different 
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types of medications. A study by Harris et al. showed that cost-sharing in the fom1 of 
prescription co-payments ranging from $1.50 to $3.00 had a significant impact on 
reducing drug utilization and drug expenditures. [12] 
PBMs often establish agreements that offer clients a network of phamiacies 
geographically accessible to their members. Typically, the phamiacies in these 
agreements are stores belonging to national or regional chains or independent community 
pharmacies. The pharmacies' incentive to participate is based upon their access to the 
large customer base. In exchange, the pharmacies agree to a reimbursement fonnula 
established by the PBM. This generally is expressed as a discount off the average 
wholesale price (A WP) plus a dispensing fee for each prescription filled. PBMs 
responding to a survey in 1997 indicated that 71 % of the prescriptions dispensed to their 
members were through network pharmacies. [1] 
Providing better access to quality pharmacies has become one of the most important ways 
to improve patient satisfaction with the pharmacy benefit. MCOs, employers, and third-
party administrators are beginning to recognize that a network having convenient, 
courteous and service oriented pharmacies translates into more satisfied customer base. 
In one study, respondents rated independent pharmacies higher than chains. [13] This 
growing realization of the influence of pharmaceutical services on patient satisfaction 
comes at a time when contracting with chain pharmacies is growing as a cost-
containment measure. Such business decisions assume that one pharmacy is as good as 
another. Previous studies of pharmacy patronage have found that personal factors 
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( including age, sex, occupation, income, and use of medication for acute or chronic 
conditions affect pharmacy selection and consumer loyalty. [14] In addition, pharmacy 
location has always played a vital role in the selection of a pharmacy. 
Managing the phannacy benefit is an increasingly complex challenge and understanding 
the impact of various plan characteristics is the first step needed to develop a well-
managed prescription benefit program. This can enable pharmacy benefit managers to 
monitor the complex effects of various plan features and to evaluate which mechanisms 
are the most effective in accomplishing desired goals. Using prescription claims data, the 
objectives of this study were: (1) to examine the relationships among plan characteristics 
and cost of pharmaceuticals within various therapeutic categories; and (2) to evaluate 
whether utilization differed among various plan characteristics after controlling for 
appropriate covariates. 
METHODOLOGY: 
Study Description: 
Data for this study were obtained from prescription claims information compiled during 
1996 for the commercial population administered by MIM Health Plans, Inc., a Rhode 
Island-based pharmacy benefit management company. These data were collected from 
pharmacies at the point of service during the routine filling of commercial members' 
prescriptions. Data elements conformed to National Council on Prescription Drug 
Processing (NCPDP) standards for pharmacy claims adjudication. Algorithms to assure 
data accuracy were applied at the point of service and retrospectively by the PBM. All 
58 
( data were blinded as to patient name assuring confidentiality of medical information. The 
study was approved by the University of Rhode Island Institutional Review Board on 
human subjects. 
Measures: 
Each record in a claims file represented a prescription dispensed to a member. The 
infonnation in the record included: pharmacy identification (NABP) number, date of 
service, national drug code (NDC) for the medication, Generic Product Identifier (GPI), 
generic name, number of prescriptions, quantity dispensed, amount paid by the member 
(co-payment), an1ount reimbursed to pharmacy provider, member identification number, 
gender, age, carrier name, account name, group name, and number of days supply. 
NABP number was used to link claims files with pharmacy files to get information on the 
name of the pharmacy, type (chain/independent) and the state in which it is located. The 
unique combination of carrier, account and group representing a particular plan was used 
to determine plan attributes such as mode of payment (FPS/capitation) and formulary 
status (open/closed/mandatory generic substitution). 
In addition to demographic information, a file on member eligibility contained each 
member's enrollment history. Each member was identified by a member number and 
may be the original enrollee (subscriber) or a dependent . Questions on continuity of 
coverage can be answered from the information in this file, which maintains a temporal 
view of the member's activity within the system. Member identification number was 
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used as a common field to link claims files with eligibility files to determine the 
members' eligibility. 
Because claims data were never structured to answer specific questions of this study, 
algorithms were designed for extracting appropriate subsets of claims using database 
management software (Dbase 2.6). The Generic Product Identifier codes (Medispan, Inc.) 
were used to divide prescription drugs into major therapeutic categories. Using pre-
collected data necessitated careful selection and examination of the data. Claims files 
were indexed with reversed claims, marked manually and deleted to ensure that the data 
for analysis did not include any denied or reversed claims. A claim reversal occurs when 
a phamrncist has to resubmit a claim due to entering the wrong information in the system 
such as a coding error or a claim with a missing drug identification code. The error is 
corrected by entering a claim identical to the first claim but with negative financial 
values. The third record reflects the correct information. 
Six therapeutic categories with the highest expenditures during fiscal year 1996 were 
selected for the analysis. These included calcium channel blocking agents, angiotensin 
converting enzyme (ACE) inhibitors, lipotropics, antidepressants, histamine H2-blockers, 
and beta-adrenergic blocking agents. 
Member-specific prescription data were extracted from the computerized records for the 
period of January 1 through December 31, 1996. All members who received at least one 
prescription for these therapeutic drug categories were included in the analysis. The total 
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f value of claims used in the analysis was $1.5 million with an average of$ 0.15 per 
member per eligible day. 
Outline of Statistical Analysis: 
The SAS program for windows (version 6.12) was used for all statistical analyses. 
Frequency analysis for categorical variables and univariate analysis for continuous 
variables was caiTied out. PROC UNIV ARIA TE and PROC PLOT were performed to 
assess the assumptions of nom1ality, linearity ai1d homoscedasticity. 
Members differed in number of days eligible during fiscal year 1996. There were cases 
where the utili zation data did not reflect a full year's experience. To adjust for this, the 
cost of prescription was divided by eligible days resulting in an estimate of the amount 
that members cost the plan per day. Therefore, the cost per member per eligible day was 
used as the dependent variable for statistical analyses. Frequency analysis revealed 
relatively few claims in states other than Tennessee. To avoid the problem of small 
numbers and unstable estimates, claims from states other than Tennessee were combined 
to form one category of "other states". Other states included: Rhode Island, Virginia, 
Georgia, New Jersey etc. 
Claims for Ca-channel blockers, lipotropics, ACE inhibitors and beta-blockers were 
combined and designated as claims for cardiovascular drugs. Claims for the remaining 
two drug categories (antidepressants and histamine H2-blockers) were also combined. 
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( Finally claims for all six-drug categories were combined which resulted in nine sets of 
claims for analysis after considering each drug category individually. 
Multiple regression analyses using PROC REG were canied out to examine the 
relationships among plan characteristics and cost of pharmaceuticals for six drug 
catego1ies and their combinations. The independent variables included in the analyses 
were number of days eligible, number of members eligible (group size), average 
wholesale price, out of pocket expense, number of days supply and quantity dispensed. 
Variance inflation factor tests were used to determine if multicollinearity problems 
existed. 
In order to ensure a valid comparison, analyses of covariance (ANCOV A) were used to 
evaluate the differences in utilization among plan characteristics using cost of 
pharmaceuticals per member per eligible day as the dependent variable. ANCOV A 
allowed us to hold factors that might influence the cost of pharmaceuticals constant and 
to observe the differences only due to plan characteristics. Out-of-pocket expense was 
analyzed after being categorized into four (dollar) groups; 0-3, >3-9, >9-12, >12. The 
control variables were member age, group size, average wholesale price and number of 
days supply. Changes in the average wholesale price (A WP) that manufacturers charge 
for each unit of their product is an indicator of price inflation while days supply reflects 
the quantity dispensed. In some cases we found significant interaction between variables 
of interest (grouping variables) and the covariate indicating violation of the assumption of 
homogeneity ofregression. Effect sizes of interactions between grouping variables and 
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( the covariate were calculated. To understand the relative differences between groups, we 
also computed least square adjusted means which held the covariates constant. A value of 
p <=0.05 was chosen as the a priori level of significance. 
Two-way ANCOV As between phannacy type and location and between out of pocket 
expense and quantity dispensed were also carried out. 
RESULTS: 
Sample Description: 
Table 1 provides information about the characteristics of enrollees. There were 29,211 
subscribers (card holders) representing 64,815 enrollees eligible during fiscal year 1996. 
The mean age of enrollees was 31.5 years. Females comprised 52.8 % of the eligible 
population and males comprised 47.2 %. There were 58.2% of members in capitation 
plans and rest in FFS plans. Members were mainly enrolled in plans with open fonnulary 
(79%) followed by mandatory generic substitution (19.6%) and closed formulary (1.4%). 
Results of Multiple Regression Models: 
Table 2 summarizes results of the multiple regression using cost per member per eligible 
day as the dependent variable. Number of days eligible, number of members eligible, 
average wholesale price, out of pocket expense, number of days supply and quantity 
dispensed were used as independent variables. The regression models were significant at 
the 0.001 level of significance for all drug categories and their combinations. The 
explained variance in the cost of pharmaceuticals by therapeutic category ranged from 
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34.3% to 87.7%. This variance was lowest for beta-blockers and highest for 
antidepressants. Variance inflation factor tests indicated absence of multicollinearity. 
(table 3) For the purpose of this study, cost of pharmaceuticals was defined as the dollar 
expenditure per member per eligible day for prescription drugs. 
Based upon this analysis, it was found that: 
Number of days eligible was negatively associated with the cost of pharmaceuticals for 
all drug categories and their combinations. 
The relationship between number of members eligible (group size) and cost of 
pharmaceuticals was not significant for all drug categories combined. 
Cost of pham1aceuticals was positively associated with out of pocket expense for all drug 
categories except for ACE inhibitors and antidepressants. 
Number of days supply was positively associated with cost of pham1aceuticals for all 
drug categories except for antidepressants. 
Cost of phannaceuticals was positively associated with quantity dispensed for all drug 
categories and their combinations. 
Results of Analyses of Covariance: 
For the purpose of this study, utilization was defined as the average dollar expenditure 
per member per eligible day for prescription drugs. Average wholesale price and days 
supply were selected as covariates because controlling for age and number of members 
eligible did not significantly improve the model fit (R2). In some cases, interactions 
between average wholesale price and grouping variables as well as days supply and 
grouping variables were significant. Effect sizes of these interactions were calculated. 
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( Values of these effect sizes, which approached zero, allowed the use of average 
wholesale price and days supply as covariates without violating the assumptions of 
ANCOVA. (table 10, 11) Least square means (LSMEANS) adjusted for average 
wholesale price and days supply were examined. 
There were significant differences in utilization among various co-payment levels. 
Utilization was lowest for co-pay level of$> 3-9 for all drug categories except for ACE 
inhibitors. (table 4) Significant differences in utilization were observed between the 
capitation and FFS mode of reimbursement. Utilization was consistently lower under 
capitation payment for all drug categories and their combinations. (table 5) In addition, 
there were significant differences in utilization among various fommlary strategies. 
(table 6) Utilization was consistently lowest for members whose plans included 
mandatory generic substitution and highest for those in closed formularies. 
Table 7 presents the results of analyses of covariance using cost per member per eligible 
day as a dependent variable and type of pharmacy as an independent variable for six drug 
categories and their combinations. There were significant differences in utilization 
between independent pharmacies and chain pharmacies; independent pharmacies being 
consistently lower. Two-way analyses of covariance were conducted with type of 
pharmacy and location of pharmacy as the independent variables. Considering all of the 
states together with the exception of Tennessee, utilization was highest for independent 
pharmacies located in the states as a group other than Tennessee. (table 8) 
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( Least square means adjusted for average wholesale price showed that utilization was 
highest for co-payment levels greater than $12.00 combined with prescriptions for more 
than 30 days supply for all drug categories except ACE inhibitors. (table 9) 
DISCUSSION: 
Several limitations should be considered before discussing the results of this study. The 
major limitation is the comprehensiveness of the data. The database includes only 
products covered by the drug benefit plans. Non-prescription drugs, samples and non-
fmmulary items (when paid for with cash by members) are typically not included. In 
cases where the cost of the prescription is less than the member's co-payment, the claim 
may not be recorded. Underreporting occurs with most third-party presc1iption databases 
[15] and may be a limitation in this study. Lastly, prescriptions filled from "out-of-
network" pharmacies were not captured. Once coverage under a plan is established, the 
pharmacist submits a claim directly to the PBM for each prescription filled. Since 
pharmacy reimbursement is dependent on the submission of a claim, there are clear 
incentives for pharmacists to submit all eligible claims. The accuracy of the claim is 
monitored by the PBM through various audit checks. These data provide an accurate 
estimate of prescription drug expenditures under a defined coverage package. The study 
is also limited in terms of generalizability and it is possible that the general population 
behaves differently from the study population. Therefore, careful consideration should be 
used before extrapolating these findings beyond the study population. 
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It was not possible to separate out the impact of individual plan characteristics on the cost 
of pharmaceuticals due to the limitations of data provided. For example, plans with 
capitation as a mode of payment had various fomrnlary strategies. Therefore, the impact 
of mode of payment on the cost of phannaceuticals may be confounded by the effect of 
various formulary strategies. It should be noted that drug benefit plans differ not only in 
various features but also in population characteristics. The effect of a particular plan 
feature on the cost of phamrnceuticals may not be due to that feature alone but may be 
caused by differences in population characteristics. In this scenario, a prospective and 
experimentally controlled design may be more desirable than the retrospective and 
observational design of this study. This study sheds light on effect of plan characteristics 
on the cost of pharmaceuticals. The results should be representative of what happens 
when vaiious pharmaceutical cost-containment measures are used. 
The variance in the cost of pharmaceuticals explained by plan characteristics ranged from 
34% to 87%. This is unusually high for regression models in which the unit of 
observation is the individual member's costs. It is well recognized that individuals' health 
care costs are largely random and reflect the unpredictability of illnesses which require 
care. The explained variance for antidepressants (87%) is impressive since this drug 
category has been associated with strong growth in recent years. [5, 1) 
Number of days eligible was negatively associated with the cost of pharmaceuticals. This 
inverse relationship between cost of pharmaceuticals and the length of time that an 
individual has been eligible may be an important finding for pharmacy benefit managers 
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( in budgeting for program costs. Stuart et al. in 1993 found a strong positive relationship 
between drug use and the length of time members were in the PACE (Phamiaceuticals 
Assistance Contract for the Elderly) program. [ 16) However, this result was not 
comparable with the results of our study. Unlike the employed population of our study, 
PACE is a voluntary social service program which is comprised of elderly people. 
For all drug categories combined, the relationship between cost of pharmaceuticals and 
number of members eligible was not significant. This finding shows the relative 
unimportance of group size on cost of pharmaceuticals and indicates business opportunity 
for PB Ms to contract with employers irrespective of company size. 
Number of days supply was positively associated with cost of pharmaceuticals. This is 
consistent with the experience that Express ScriptsNalueRx had with their clients. [5] 
Effect of Plan Characteristics on the Cost of Pharmaceuticals: 
Co-payment: 
The co-payment amount for different plans ranged from $1.00 to $9.00 for generics and 
greater than $9.00 for brand name products. The co-payment amount of >$3.00-9.00 was 
associated with lowest utilization for all drug categories except for ACE inhibitors. This 
can be partially explained by the co-payment structure encouraging the use of generics. 
This co-payment structure might have resulted in the prescribing and dispensing of 
lower-cost generic products and ultimately lower utilization for co-payments ranging 
between $3.00 and $9.00. This explanation is supported by the results of a study which 
demonstrated that cost-sharing differentials between generic and brand name products 
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( were associated with higher rates of generic drug use. [15] It is logical to expect 
prescribers to increase the average prescription size as a result of co-payment. An 
increased prescription size means that members receive a longer duration of therapy, 
thereby reducing the number of members' co-payments and increasing the average cost. 
Two-way analyses of covariance between co-payment and days supply showed that 
higher copay (greater than $12.00) and higher days supply (more than 30 days) was 
associated with highest utilization for all drug categories except ACE inhibitors. 
Ingredient cost inflation could counter the net effect of co-payment. By controlling for 
days supply and average wholesale price the confounding of results was prevented. 
Mode of Payment: 
Utilization was consistently lower for capitation than FFS for all drug categories and their 
combinations. The results may be encouraging for those PBMs who are accepting 
capitation as a mode of payment. The difference in utilization between capitated and FFS 
plans may be attributable to the reimbursement differences between them. Under 
capitation, PBMs' revenue is a function of the number of members eligible and not the 
number of prescriptions dispensed. As a consequence it is anticipated under capitation 
that PBMs would make an effort, when appropriate, to alter physician prescribing and 
pharmacist dispensing behavior in an effort to minimize program costs. 
Formulary Status: 
Plans with mandatory generic substitution demonstrated the lowest utilization among all 
drug categories and their combinations. These utilization patterns are likely attributable to 
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( the lower costs of ingredients for generic drugs. These results are promising for phamiacy 
benefit managers since patents for a large number of commercially important drugs are 
scheduled to expire within the next few years thereby making generic substitution an 
important source of savings in drug benefit expenditures in the near future. Analysts 
project that generics may account for up to 65% of all prescriptions dispensed by the end 
of the decade. [17) 
Closed fo1mularies were associated with the highest utilization for all drug categories and 
their combinations. This is contradictory to the literature on fonnulary research which 
shows that an association exists between decreased cost and a well-controlled fmmulary. 
[8, 18, 19) The results have practical significance since there is a trend towards the 
development of more restrictive formularies. [20, 6) There are two possible explanations 
for the finding that closed formularies were associated with high utilization. First, the 
number of members enrolled in plans with closed fonnularies was significantly lower 
(1.4%) than members enrolled in plans with open formularies and mandatory generic 
substitution. Higher utilization among a small number of members may have resulted in 
higher utilization. However, the number of members eligible was used as one of the 
covariates and did not significantly improve explained variance. 
Second, and most important, drug product manufacturers enter into rebate contracts with 
PBMs. The rebate amount paid by a manufacturer to a PBM is based on formulary 
exclusivity, sales volume and market share movement. The traditional rebate contracts 
are for brand name drugs. A study indicated that rebates for a specific product may be as 
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high as 22.5% of the product's sales. [2] The cost data used in this study have not been 
adjusted for rebates and, therefore, may be overestimates of the true costs. 
Pharmacy Type: 
Utilization was lower for independent pham1acies than chain pham1acies for all drug 
categories and their combinations. There are two possible explanations for this finding . 
First, network participation, drug availability, convenience and cost may be influential on 
patients' choice of pharmacies. There is a possibility that ce1iain pharmacies may be 
selected by members requiring high-cost medications, resulting in high utilization for 
those pham1acies. Second, pharmacies vary with regard to the amount below A WP that 
they were paid for ingredient costs. These results indicate to PBMs and network 
phannacies the importance of contract negotiation. Two-way analyses of covariance 
between pharmacy type and location indicated pharmacies located in Tennessee, 
irrespective of type, were lower utilizers than pharmacies located in other states 
(evaluated as a group) for all drug categories except for ACE inhibitors. 
CONCLUSION: 
The primary objective of this study was to evaluate whether there were differences in 
utilization among various plan characteristics after controlling for appropriate covariates 
using prescription claims data. The secondary objective was to assess the relationship 
among plan characteristics and cost of pharmaceuticals within various therapeutic 
categories. 
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( Information for six drug categories was extracted from claims data using database 
management software. Statistical analyses utilizing multiple regression and analysis of 
covariance were carried out. Plan characteristics explained 34-87% of variance in the cost 
of phamrnceuticals. These included number of days eligible, number of members eligible, 
average wholesale price, member co-payment, number of days supply and quantity 
dispensed. This is unusually high for regression models where unit of observation is the 
individual member's costs. An inverse relationship was found between cost of 
phaimaceuticals and the length of time that an individual is eligible. This finding may 
help PBMs in budgeting by knowing that people who remain in a prescription benefit 
program for a long period of time tend to have lower drug costs. Also, the non-significant 
relationship that was found between cost of pharmaceuticals and number of members 
eligible indicated a lack of importance of group size in contracting with a client. Number 
of days supply was positively associated with cost of pharmaceuticals. This association 
may justify days supply limits imposed by PBMs in an effort to contain cost. 
The co-payment amount for different plans ranged from $1.00 to $9.00 for generics and 
greater than $9.00 for brand name products. Utilization was lowest for co-payments 
ranging between $3.00 and $9.00. This may have resulted from more use of lower cost 
generic products due to co-payment differentials between generic and brand name 
products. Capitation as a mode of payment was associated with lower utilization than 
FFS. This finding may be encouraging to those PBMs who are accepting the capitation 
method ofreimbursement. Closed formularies were associated with higher utilization 
than open formularies or mandatory generic substitution. This result indicates the 
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( importance of adjusting cost of pharmaceuticals for rebates before evaluating various 
fonnulary strategies. Significant differences in utilization were found between 
independent pharmacies and chain pharmacies. The implications of these findings 
suggest the importance of contract negotiation with phannacies. 
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( TABLE: 1 CHARACTERISTICS OF ENROLLEES IN A PRIVATE THIRD-PARTY PRESCRIPTION PROGRAM: • 
MEMBERAGET 
1-5 
6-20 
21-40 
41-64 
>64 
Mean 
MEMBER GENDERT 
FEMALE 
MALE 
MODE OF PAYMENT 
CAPITATION 
FEE FOR SERVICE 
FORMULARY STATUS 
CLOSED 
MANDATORY GENERIC SUBSTITUTION 
OPEN 
*: As of December 31 , 1996 
t: 323 missing age records 
t: 86 missing gender records 
# OF PARTICIPANTS(%) 
(N= 64815) 
5666 (8.8) 
13947 (21.6) 
23739 (36.8) 
18788 (29.1) 
2352 (3 .6) 
31.5 
34145 (52.8) 
30584 (47.2) 
37696 (58.2) 
27119 (41.8) 
906 (1.4) 
12679 (19.6) 
51230 (79.0) 
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TABLE: 2 MULTIPLE REGRESSION MODEL OF COST OF PHARMACEUTICALS FOR VARIO US DRUG CATEGORIES. 
REGRESSION COEFFICIENTS (STANDARD ERROR) FOR COST OF PHARMACEUTICALS BY PLAN CHARACTERISTICS: 
VARIABLE 
INTERCEPT 
# OF DAYS ELIGIBLE 
# OF MEMBERS ELIGIBLE 
AVERAGE WHOLESALE 
PRICE 
OUT OF POCKET 
EXPENSE 
# OF DAYS SUPPLY 
QUANTITY DISPENSED 
N 
F 
R2 
ADJ.R2 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
I 
-
-0.4589 
(0.0000) 
0.0228 
(0.0033) 
0.6216 
(0.0043) 
0.0018 
(0.0097) 
0.1324 
(0.0170) 
0.4721 
(0.0144) 
6519 
3800.21~ 
0.7778 
0.7776 
2 
-
-0.3722 
(0.0000) 
0.0557~ 
(0.0054) 
0.6764 
(0.0042) 
0.0493 
(0.0165) 
0.2761 
(0.0238) 
0.2101 
(0.0186) 
3343 
1752.17~ 
0.7591 
0.7586 
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3,4) 
3 
-
-0.4697 
(0.0000) 
0 .0629~ 
(0.0036) 
0.3327 
(0.0305) 
-0.1721 
(0.0105) 
0.0306 
(0.0001) 
0.6542~ 
(0.0147) 
5651 
2993.54 
0.7609 
0.7606 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS (5,6) 
9: COMBINING ALL SIX DRUG CATEGORIES 
DRUG CATEGORY 
4 5 
- -
-0.2053 -0.3726 
(0.0001) (0.0000) 
-0.0452~ 0.02361 
(0.0160) (0.0062) 
0.3291 0.3940 
(0.0390) (0.0073) 
0.2076 0.1695 
(0.0412) (0.0170) 
0.1210 0.0535 
(0.0091) (0.0043) 
0.2673~ 0.5520 
(0.0557) (0.0271) 
3184 4462 
278.68~ 1251.00 
0.3448 0.6275 
0.3435 0.6270 
*:significant at 0.001 
t: significant at 0.05 
6 
-
-0.2547 
(0.0000) 
0.0146 
(0.0040) 
0.9571 
(0.0089) 
-0.0258 
(0.0160) 
-0.0143 
(0.0028) 
0.4293 
(0.0145) 
7809 
9361.93 
0.8780 
0.8779 
7 8 
- -
-0.3105 -0.2670 
(0.0000) (0.0000) 
0.0042 0.0185 
(0.0035) (0.0045) 
0.6376 0.7164 
(0.0083) (0.0092) 
0.0824 0.1171 
(0.0097) (0.0150) 
0.0696 -0.0116 
(0.0023) (0.0029) 
0.3792 0.4765 
(0.0141) (0.0157) 
18700 12372 
5058.47 5032.43 
0.6188 0.7094 
0.6187 0.7093 
., 
9 
-
-0.2785 
(0.0000) 
0.0059 
(0.0029) 
0.6405 
(0.0027) 
0.1284 
(0.0084) 
0.0453 
(0.0018) 
0.3937 
(0.0105) 
31073 
9109.77 
0.6376 
0.6375 
-..) 
°' 
TABLE: 3 MULTICOLLINEARITY DIAGNOSTIC 
VARIANCE INFLATION FACTOR OF INDEPENDENT VARIABLES FOR MULTIPLE REGRESSION MODELS: 
VARIABLE 
INTERCEPT 
#OF DAYS ELIGIBLE 
# OF MEMBERS ELIGIBLE 
A VERA GE WHOLESALE PRICE 
OUT OF POCKET EXPENSE 
# OF DAYS SUPPLY 
QUANTITY DISPENSED 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
1 
-
1.0380 
1.0344 
1.1336 
1.0677 
1.9464 
2.0193 
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3,4) 
2 
-
1.0297 
1.0632 
1.3307 
1.0724 
1.16673 
1.7769 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS (5,6) 
9: COMBINING ALL SIX DRUG CATEGORIES 
DRUG CATEGORY 
3 4 5 6 
- - - -
1.0704 1.0646 1.0669 1.0974 
1.0648 1.1546 1.0971 1.1068 
1.0058 1.1064 1.2471 2.0345 
1.0347 1.1636 1.0910 1.8163 
1.8436 1.9198 2.4860 1.4767 
1.8077 1.8827 2.4676 1.6724 
--....., 
7 8 9 
- - -
1.0471 1.0851 1.0588 
1.0622 1.1008 1.0713 
1.1584 1.5358 1.1852 
1.0775 1.3917 1.1368 
1.9350 1.6233 1.6813 
1.9749 1.7419 1.7239 
-.J 
-.J 
-
TABLE: 4 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY OUT OF POCKET EXPENSE FOR VARIO US DRUG 
CATEGORIES: 
ANOVA 
F(p) 
R-
ANCOV A (COVARIATE) 
MEMBER AGE 
F(p) 
R-
#OF MEMBERS ELIGIBLE 
F(p) 
R-
AVERAGE WHOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R-
LS.MEANS 
0-3 
>12 
>3-9 
>9-12 
I: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
I 2 
93.63 86.22 
(0.0001) (0.0001) 
0.0396 0.0692 
90.42 74.11 
(0.0001) (0.0001) 
0.0504 0.0786 
70.39 64.82 
(0.0001) (0.0001) 
0.0399 0.0699 
1157.39 1158.52 
(0.0001) (0.0001) 
0.4597 0.6252 
0.0947 0.1311 
0.0976 0.1301 
0.0855 0.1123 
0.0974 0.1355 
4: BETA-BLOCKERS 
5: HZ-BLOCKERS 
6: ANTI DEPRESSANTS 
3 
30.92 
(0.0001) 
0.0156 
48.47 
(0.0001) 
0.0322 
23.22 
(0.0001) 
0.0159 
548.27 
(0.0001) 
0.3203 
0.0885 
0.0527 
0.0730 
0.0631 
DRUG CATEGORY 
4 5 6 7 
146.61 227.15 1549.18 475 .73 
(0.000 1) (0.0001) (0.0001) (0.000 1) 
0.1076 0.1234 0.3473 0.0673 
110.01 188.32 1181.42 410.31 
(0.000 I) (0.000 I) (0.0001) (0.0001) 
0.1077 0.1347 0.3511 0.0767 
113 .16 160.83 1175.38 360.53 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.1111 0.1185 0.3520 0.0685 
205.48 457.15 3466.12 3082.62 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.2199 0.3209 0.6679 0.4383 
0.0191 0.1877 0.0969 0.0599 
0.0544 0.2034 0.1047 0.0740 
0.0189 0.1037 0.0496 0.0601 
0.0462 0.1784 0.0909 0.0779 
7: COMB INING CARDIOVASCULAR DRUGS (1,Z,3,4) 
8: COMB INING HZ-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBIN ING ALL SIX DRUG CATEGORIES 
8 9 
1209.26 1535.40 
(0.0001) (0.0001) 
0.2108 0.1214 
953.86 1167.29 
(0.0001) (0 .0001) 
0.2194 0.1228 
901.96 1143 .89 
(0.0001) (0.0001) 
0.2116 0.1216 
2612.05 5638.42 
(0.0001) (0.0001) 
0.4903 0.4582 
0.0954 0.0688 
0.1384 0.0971 
0.0780 0.0663 
0.1168 0.0939 
...... 
-i 
00 
TABLE: 5 ANALYSIS OF COY ARIAN CE OF COST OF PHARMACEUTICALS BY MODE OF PAYMENT FOR VARIO US DRUG 
CATEGORIES: 
ANOVA 
F(p) 
RL 
ANCOVA (COVARIATE) 
MEMBER AGE 
F ( p) 
RL 
#OF MEMBERS ELIGIBLE 
F(p) 
R-z-
AVERAGE WHOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R-
LS MEANS 
CAPITATION 
FEE FOR SERVICE 
I: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 3 
227.30 30.65 169.32 
(0.0001) (0.0001) (0.0001) 
0.0323 0.0087 0.0282 
139.91 30.78 117.17 
(0.0001) (0.0001) (0.0001) 
0.0395 0.0174 0.0387 
131.40 26.76 91.82 
(0.0001) (0.0001) (0.0001) 
0.0374 0.0152 0.0309 
2074.86 1901.51 841.65 
(0.0001) (0.0001) (0.0001) 
0.4778 0.6215 0.3026 
0.0812 0.1213 0.0603 
0.1054 0.1336 0.0708 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
6:ANT!DEPRESSANTS 
DRUG CATEGORY 
4 5 6 7 8 
123.66 255.07 35.55 333.13 9.31 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0023) 
0.0327 0.0500 0.0040 0.0165 0.0006 
66.63 157.06 33.08 210.73 7.66 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0005) 
0.0352 0.0609 0.0075 0.0208 0.0011 
61.98 143.68 30.35 167.79 5.34 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0048) 
0.0331 0.0566 0.0069 0.0168 0.0007 
306.46 828.36 5518.96 5115.96 4357.58 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
0.2014 0.3393 0.6576 0.4372 0.4905 
0.0157 0.1160 0.0736 0.0607 0.0901 
0.0310 0.2072 0.1009 0.0768 0.1238 
7: COMBINING CARDIOVASCULAR DRUGS (I,2,3,4) 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
9 
152.81 
(0.0001) 
0.0045 
76.50 
(0.0001) 
0.0045 
76.63 
(0.0001) 
0.0046 
9197.68 
(0.0001) 
0.4529 
0.0722 
0.0921 
-...] 
\0 
TABLE: 6 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY FORMULARY STATUS FOR VARIOUS DRUG 
CATEGORIES: 
ANOVA 
F(p) 
R' 
ANCOVA (COVARIATE) 
MEMBER AGE 
F(p) 
R-
#OF MEMBERS ELIGIBLE 
F(p) 
R' 
A YERAGE WHOLESALE 
PRlCE AND DAYS SUPPLY 
F(p) 
R-
LS MEANS 
CLOSED 
OPEN 
MANDATORY GENERJC 
SUBSTITUTION 
I: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 
155.63 107.77 
(0.0001) (0.0001) 
0.0437 0.0584 
125.00 82.76 
(0.0001) (0.0001) 
0.0522 0.0667 
108.46 72.41 
(0.0001) (0.0001) 
0.0459 0.0592 
1573.79 1433.91 
(0.0001) (0.0001) 
0.4806 0.6228 
0.6534 0.3526 
0.0942 0.1300 
0.0900 0.1226 
4: BET A-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
3 
114.42 
(0.0001) 
0.0378 
100.53 
(0.0001) 
0.0492 
80.96 
(0.0001) 
0.0405 
683.38 
(0.0001) 
0.3197 
0.2442 
0.0652 
0.0626 
DRUG CATEGORY 
4 5 6 7 
19.94 302.29 24.37 63.21 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.0108 0.1110 0.0055 0.0063 
13.32 209.02 41.40 90.58 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.0108 0.1147 0.0140 0.0135 
17.16 213.45 16.28 60.44 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.0140 0.1180 0.0056 0.0091 
223 .60 709 .22 4517 .24 3933.52 
(0.0001) (0.000 1) (0.0001) (0.0001) 
0.1970 0.3696 0.6771 0.4434 
0.0611 0.7353 0.3733 0.2751 
0.0296 0.1495 0.0857 0.0728 
0.0147 0.1418 0.0703 0.0565 
7: COMBINING CARDIOVASCULAR DRUGS (1 ,2,3,4) 
8: COMB INING H2-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
8 9 
117 .29 261.53 
(0.0001) (0.0001) 
0.0169 0.0154 
79.08 175.70 
(0.0001) (0.0001) 
0.0171 0.0155 
79.56 183.71 
(0.0001) (0.0001) 
0.0174 0.0164 
3626.74 7420.19 
(0.0001 ) (0.0001) 
0.5166 0.4710 
0.4360 0.3389 
0.1048 0.0847 
0.0872 0.0669 
00 
0 
TABLE: 7 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY PHARMACY TYPE FOR VARIO US DRUG 
CATEGORIES: 
ANOVA 
F ( p) 
R-
ANCOVA (COVARIATE) 
MEMBER AGE 
F(p) 
R-
#OF MEMBERS ELIGIBLE 
F(p) 
R' 
AVERAGE WHOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R-
LS MEANS 
CHAIN 
INDEPENDENTS 
I: Ca CHANNEL BLOCKERS 
Z: LIPOTROPICS 
3: ACE rNH!BITORS 
1 2 3 
76.40 39.77 47.92 
(0.0001) (0.0001) (0.0001) 
0.0111 0.0113 0.0081 
97.08 42.32 77.57 
(0.0001) (0.0001) (0.0001) 
0.0277 0.0237 0.0259 
39.98 23.91 25.30 
(0.0001) (0.0001) (0.0001) 
0.0116 0.0136 0.0087 
1894.87 1886.60 805.63 
(0.0001) (0.0001) (0.0001) 
0.4552 0.6196 0.2935 
0.0969 0.1336 0.0672 
0.0833 0.1054 0.0598 
4: BET A-BLOCKERS 
5: HZ-BLOCKERS 
6:ANTIDEPRESSANTS 
DRUG CATEGORY 
4 5 6 7 8 
44.00 61.46 0.28 132.71 9.84 
(0.0001) (0.0001) (0.5936) (0.0001) (0.0017) 
0.0119 0.0125 0.0000 0.0066 0.0007 
22.11 85.07 23 .24 159.15 9.51 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
0.0119 0.0339 0.0052 0.0158 0.0013 
43.25 33 .28 2.80 80.57 8.05 
(0.0001) (0.0001) (0.0610) (0.0001) (0.0003) 
0.0233 0.0137 0.0006 0.0081 0.0011 
227.82 584.22 5294.23 4912.71 4180.80 
(0.0001) (0.0001) (0.0001) (0.000 1) (0.0001) 
0.1579 0.2659 0.6482 0.4273 0.4802 
0.0252 0.1620 0.0860 0.0714 0.1057 
0.0185 0.1439 0.0831 0.0617 0.1052 
7: COMBINING CARDIOVASCULAR DRUGS (1,Z,3,4) 
8: COMBINING HZ-BLOCKERS AND ANTI DEPRESSANTS 
9: COMB INING ALL SIX DRUG CATEGORIES 
9 
116.44 
(0.0001) 
0.0034 
61.76 
(0.0001) 
0.0036 
66.01 
(0.0001) 
0.0039 
8884.24 
(0.0001) 
0.4443 
0.0838 
0.0761 
'\ 
00 
TABLE: 8 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY PHARMACY TYPE AND LOCATION FOR VARIOUS 
DRUG CATEGORIES: 
ANOVA 
F(p) 
Ri 
ANCOVA (COVARIATE) 
MEMBER AGE 
F ( p) 
R-
# OF MEMBERS ELIGIBLE 
F(p) 
R-
AVERAGE WHOLESALE 
PRICE AND DAYS SUPPLY 
F(p) 
R-
LS MEANS 
CHAIN - OTHER 
CHAIN-TN 
INDEPENDENT-OTHER 
INDEPENDENTS - TN 
I: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 
288.25 165.01 
(0.0001) (0.0001) 
0.1130 0.1248 
230.29 130. 10 
(0.0001) (0.0001) 
0.1195 0.1304 
216.79 123.99 
(0.0001) (0.0001) 
0.1139 0.1259 
1139.29 1133.13 
(0.0001) (0.0001) 
0.4565 0.6202 
0.0946 0.1289 
0.0943 0.1303 
0.1329 0.1534 
0.0928 0.1206 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
3 
202.23 
(0.0001) 
0.0946 
164.37 
(0.0001) 
0.1019 
150.90 
(0.000 1) 
0.0951 
486.68 
(0.000 1) 
0.2954 
0.0624 
0.0659 
0.0504 
0.0677 
6: ANTI DEPRESSANTS 
DRUG CATEGORY 
4 5 6 7 8 9 
89.06 217.67 15.21 435.46 117.04 425.23 
(0.0001) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
0.0685 0.1197 0.0052 0.0621 0.0253 0.0369 
67 .74 185 .72 25 .90 346.77 88.03 320.65 
(0.000 1) (0.0001) (0.0001) (0.0001) (0.0001) (0.0001) 
0.0694 0.1340 0.0117 0.0657 0.0253 0.0371 
82.12 167.42 13.15 338.06 91.55 325.72 
(0.0001) (0.0001 ) (0.0001) (0.0001) (0.0001) (0.0001) 
0.0835 0.1237 0.0060 0.0647 0.0266 0.0380 
145.64 356.45 3171.99 2947.01 2524.06 5327.21 
(0.0001 ) (0.000 1) (0.0001) (0.0001) (0.0001) (0.0001) 
0.1670 0.2708 0.6484 0.4278 0.4827 0.4449 
0.0337 0.1881 0.0881 0.0714 0.1223 0.0881 
0.0222 0.1548 0.0848 0.0686 0.1007 0.0810 
0.0514 0.2832 0.1568 0.0735 0.1971 0.1009 
0.0198 0.1522 0.0861 0.0689 0.11 59 0.0829 
7: COMBINING CARDIOVASCULAR DRUGS (I ,2,3,4) *: TENNESSEE 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
00 
N 
TABLE: 9 ANALYSIS OF COVARIANCE OF COST OF PHARMACEUTICALS BY OUT OF POCKET EXPENSE AND# OF DAYS SUPPLY 
FOR VARIOUS DRUG CATEGORIES: 
ANOVA 
F(p) 
R" 
ANCOV A (COY ARIA TE) 
MEMBER AGE 
F(p) 
R-
#OF MEMBERS 
ELIGrBLE 
F(p) 
R--r 
AVERAGE WHOLESALE 
PRICE 
F(p) 
R-
LS MEANS 
(0-3) - 30 
(0-3) - > 30 
(>12)- 30 
(>12) - >30 
(>3-9) - 30 
(>3-9) - >30 
(>9-12)-30 
(>9-12)- >30 
I: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
1 2 
174.59 166.97 
(0.0001) (0.0001) 
0.1523 0.2519 
163.46 153.46 
(0.0001) (0 .0001) 
0.1613 0.2613 
155.59 145.41 
(0.0001) (0.0001) 
0.2231 0.3107 
593 .03 689.34 
(0.0001) (0.0001) 
0.4110 0.6138 
0.0910 0.1137 
0.1831 0.2933 
0.0836 0.1066 
0.2931 0.3607 
0.0760 0.0963 
0.1067 0.2665 
0.0871 0.1165 
0.2058 0.2986 
4: BETA-BLOCKERS 
5: H2-BLOCKERS 
3 
134.84 
(0.0001) 
0. 1396 
129.81 
(0.0001) 
0.1515 
119.87 
(0.0001) 
0.2145 
275 .23 
(0.0001) 
0.2747 
0.0785 
0.2797 
0.0456 
0.1635 
0.0644 
0.1155 
0.0570 
0.1249 
6: ANTI-DEPRESSANTS 
DRUG CATEGORY 
4 5 6 7 
106.44 200.82 714.02 452.78 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.1698 0.2252 0.3641 0.1383 
93.18 184.23 632.73 423.15 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.1699 0.2336 0.3670 0.1463 
100.44 177.32 638.44 417.35 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.2199 0.4714 0.5037 0.2437 
124.53 233.39 2065 .26 1791.25 
(0.0001) (0.0001) (0.0001) (0.0001) 
0.2148 0.2786 0.6573 0.4205 
0.0165 0.1798 0.0936 0.0556 
0.0429 0.1805 0.1279 0.1091 
0.0443 0.1811 0.0994 0.0620 
0.1713 0.6477 0.2455 0.2199 
0.0154 0.0918 0.0449 0.0523 
0.0423 0.1494 0.1189 0.0973 
0.0414 0.1582 0.0858 0.0692 
0.0778 0.4965 0.1952 0.1558 
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3,4) 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
8 9 
619.26 919.70 
(0.0001) (0.0001) 
0.2421 0.1619 
561.07 808.26 
(0.0001) (0.0001) 
0.2485 0.1625 
548.05 817.73 
(0.0001) (0.0001) 
0.4248 0.2839 
1533.64 3299.19 
(0.0001) (0.0001) 
0.4748 0.4419 
0.0921 0.0652 
0.1174 0.1084 
0.1278 0.0844 
0.3761 0.2760 
0.0707 0.0589 
0.1206 0.1103 
0.1073 0.0847 
0.2971 0.1253 
00 
w 
TABLE: 10 EFFECT SIZE OF INTERACTION BETWEEN DAYS SUPPLY (COVARIATE) AND GROUPING VARIABLE FOR VARIOUS 
DRUG CATEGORIES: 
GROUPING V ARlABLE 
1 z 
MODE OF PAYMENT 0.0003 0.0004 
OUT OF POCKET EXPENSE 0.0035 0.0004 
FORMULARY STATUS 0.0004 -0.000Z 
PHARMACY TYPE 0.0004 ·o.ooz5 
PHARMACY TYPE AND LOCATION 0.0063 0.0030 
1: Ca CHANNEL BLOCKERS 
Z: LIPOTROPICS 
3: ACE INHIBITORS 
4: BETA-BLOCKERS 
5: HZ-BLOCKERS 
6: ANTI DEPRESSANTS 
DRUG CATEGORY 
3 4 5 6 7 
0.0005 0.0051 0.0030 0.0008 0.0005 
0.0011 0.0013 0.0093 0.0013 O.OOlZ 
O.OOlZ O.OOZ7 o.oozz 0.0000 0.0005 
-0.0001 0.0001 O.OOOZ 0.0000 0.0009 
0.0018 -0.0001 0.0016 0.0005 0.0010 
7: COMBINING CARDIOVASCULAR DRUGS ( l ,Z,3,4) 
8: COMBINING HZ-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
8 
0.0015 
0.0019 
0.0004 
0.0000 
o.oooz 
9 
0.0010 
0.0008 
0.0004 
o.oooz 
O.OOOZ 
00 
""' 
-- ., 
TABLE: 11 EFFECT SIZE OF INTERACTION BETWEEN AVERAGE WHOLESALE PRICE (COVARIATE) AND GROUPING VARIABLE 
FOR VARIOUS DRUG CATEGORIES: 
GROUPING VARlABLE 
1 2 
MODE OF PAYMENT 0.0024 0.0004 
OUT OF POCKET EXPENSE 0.0092 0.0133 
FORMULARY STATUS 0.0015 0.0026 
PHARMACY TYPE 0.0000 0.0001 
PHARMACY TYPE AND LOCATION 0.0006 0.0038 
OUT OF POCKET EXPENSE AND # 0.0084 0.0151 
OF DAYS SUPPLY 
1: Ca CHANNEL BLOCKERS 
2: LIPOTROPICS 
3: ACE INHIBITORS 
4: BET A-BLOCKERS 
5: H2-BLOCKERS 
6: ANTI DEPRESSANTS 
DRUG CATEGORY 
3 4 5 6 7 
0.0000 0.0003 0.0002 0.0166 0.0019 
0.0045 0.0034 -0.0001 0.0106 0.0049 
0.0002 0.001 l 0.0004 0.0065 0.0021 
-0.0001 0.0048 -0.0001 0.0001 0.0001 
-0.0003 0.0053 0.0007 0.0002 0.0007 
0.0065 0.0122 -0.0010 0.0112 0.0055 
7: COMBINING CARDIOVASCULAR DRUGS (1,2,3,4) 
8: COMBINING H2-BLOCKERS AND ANTI DEPRESSANTS 
9: COMBINING ALL SIX DRUG CATEGORIES 
8 9 
0.0005 0.0003 
0.0229 0.0268 
0.0070 0.0028 
0.0082 0.0004 
0.0085 0.0012 
0.0231 0.0265 
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SECTION II 
APPENDIX 
87 
SAS PROGRAM: 
OPTIONS LS=65 PS=60; 
LIBNAME ALMAS'C:\SEPTEM'; 
DATA AL MAS . BETA1; 
SET WORK.BETA1; 
IF NRXS=-1 THEN DELETE; 
RUN; 
PROC CONTENTS DATA=ALMAS.BETA1; 
RUN; 
PROC FREQ DATA=ALMAS.BETA1 ORDER=FREQ; 
TABLES CACCOUNT CBRANDNA CCARRIER CCATCODE CCHAINCO CDAWIND 
CDOSEFOR CGENIND CGENNAME CGENPROD CGROUP CLTC CMACIND 
CMCO CMEMGEND CNAME COCCUPAT CPRODTYP CREFILL CSTATE 
CSTRENGT FFSCAP FOR MULAR MANFGNAM NDAYSUPP NQTYDISP 
NRXS REGION TYPE NCOPAYAM ; 
RUN; 
OPTIONS FMTSEARCH=(ALMAS); 
PROC FORMAT LIBRARY= ALMAS; 
VALUE $CSTATE ' AL'='SE' 'KY'= ' SE ' ' MS' =' SE ' ' TN ' = ' SE' 
' AK ' = ' WT ' ' AZ ' ='WT' ' CO ' ='WT ' ' ID ' = ' WT' 
'MT' = ' WT ' 'NM' = 'WT' ' ND ' = ' WT ' ' OR ' = ' WT ' 
' SD '='WT' ' UT ' = 'WT' 'WA'=' WT ' ' WY ' =' WT' 
'CA'=' PC ' ' HI '=' PC ' ' NV '=' PC ' 
' CT '=' NE ' ' ME'= ' NE ' 'MA' = ' NE ' ' NH ' = ' NE ' 
' NY '=' NE ' ' RI ' =' NE' ' VT '= 'NE ' 
' DE '=' MA ' ' DC ' =' MA' ' MD ' = ' MA ' ' NJ ' = ' MA' 
'PA ' = ' MA ' ' VA ' = 'MA' ' WV '='MA' 
' FL ' = ' SA' ' GA'= ' SA ' ' NC ' = ' SA ' ' PR ' = ' SA ' 
' SC ' = ' SA' ' VI ' = ' SA ' 
' IL ' = ' NC ' 'IN '=' NC ' 'M I '=' NC ' ' MN ' = ' NC' 
' OH ' = ' NC ' 'WI ' = 'NC' 
' AR '=' SC ' ' IA ' = ' SC ' ' KS '=' SC ' ' LA ' = ' SC ' 
'MO' = ' SC' ' NE ' = ' SC ' ' OK '=' SC' ' TX'= ' SC ' ; 
VALUE $CGENNAME ' CIMETIDINE TAB ' = ' CIMETIDINE ' 
' FAMOTIDINE TAB ' = ' FAMOTIDINE' 
' NIZATIDI NE CAP '=' NIZATIDINE ' 
' FAMOTIDINE SUS ' ='FAMOTIDINE ' 
' RANITIDINE TAB '=' RANITIDINE '; 
88 
( VALUE $CBRANDNA ' METOPROLOL TARTRATE '=' METOPROLOL TARTRATE ' 
' PROPRANOLOL TAB 10MG'=' PROPRANOLOL ' 
' PROPRANOLOL TAB 20MG'=' PROPRANOLOL ' ; 
VALUE $CDOSEFOR 'TBCR '= 'CONTROLLED RELEASE TABLETS ' 
' CPCR '=' CONTROLLED REL EASE CAPSULES ' 
' TABS '=' TABLETS ' 
' CAPS '=' CAPSULES ' 
' POWD'=' POWDER ' 
' PACK '=' POWDER,PACKET ' 
' GRAN '= 'GRANULES ' 
' SOLN '=' SOLUTION ' 
' SYRP '= 'SYRUP ' 
' SUSP '=' SUSPENSI ON' ; 
VALUE $M EMGEND ' F ' = ' FEMALE ' 
' M'= ' MALE ' ; 
VALUE $CDAWIND ' O'= ' NO ' 
' 1 ' = ' YES ' ; 
VALUE $CMACIND ' 1 '=' NO ' 
' Y '= ' YES' ; 
VALUE $CPRODTYP ' F ' = ' PRESCRIPTION ' 
' O'=' OVER THE COUNTER ' ; 
VALUE $CGENPROD ' 1 ' = ' GENERIC ' 
' 3 ' = ' GENERIC' 
' 2 ' = ' BRAND ' ; 
VALUE $CGENIND '1 '= ' MULTIPLE SOURCE ' 
' 2'= ' SINGLE SOURCE ' ; 
VALUE $FFSCAP ' F'= ' FEE FOR SERVICE ' 
' C' = ' CAPITATION.' ; 
VALUE $FROMULAR ' C'= ' CLOSED ' 
' O' = ' OPEN' 
' M'= ' MENDATORY GENERIC SUBSTITUTION ' ; 
VALUE $COCCUPAT ' 1 '= ' MANAGEMENT ' 
'2'= ' COMMERCE' 
' 3'= ' SCIENCES ' 
'4'='HEALTH ' 
' 5'= ' SOCIAL SCIENCES, LAWYERS, EDUCATORS ' 
' 6'= ' ART' 
'?'='SALES AND SERVICES ' 
' 8'= ' TRADES AND TRANSPORT ' 
' 9'= ' PRIMARY INDUSTRIES ' 
' 10'=' MANUFACTURING ' 
' 11 ' ='CONTRACTORS ' ; 
VALUE $CCHAINCO ' ' =' INDEPENDENT ' ; 
RUN; 
89 
( DATA ALMAS.BETA2; SET ALMAS.BETA1; 
IF CGROUP='8018' THEN DELETE; 
LABEL CACCOUNT='ACCOUNT NUMBER ' 
CBRANDNA='BRAND NAME' 
CCARRIER='CARRIER NAME' 
CCATCODE= ' EXCEPTIONAL DRUG CATEGORY CODE' 
CCHAINCO='PHARMACY CHAIN CODE' 
CDAWIND='DISPENSED AS WRITTEN INDICATOR' 
CDOSEFOR='DOSAGE FORM ' 
CGENIND= ' SOURCE OF THE DRUG ' 
CGENNAME='GENERIC NAME' 
CGENPROD= ' BRAND/GENERIC' 
CGROUP='GROUP NUMBER' 
CLTC='LONG TERM CARE INDICATOR' 
CMACIND= 'MAXIMUM ALLOWABLE COST INDICATOR' 
CMCO='MANAGED CARE ORGANIZATION' 
CMEMGEND='MEMBER GENDER' 
CMEMID='MEMBER IDENTIFICATION NUMBER' 
CNAME='PHARMACY CHAIN NAME ' 
COCCUPAT='OCCUPATION OF THE MEMBER' 
CPHARMNO= ' PHARMACY NUMBER' 
CPRODTYP= ' PRESCRIPTION/OTC ' 
CREFILL='NUMBER OF REFILLS' 
CSTATE='LOCATION OF THE PHARMACY' 
CSTRENGT='STRENGTH OF THE DOSAGE FORM' 
DAWP1='DATE OF AVERAGE WHOLESALE PRICE' 
DSERVICE='DATE OF SERVICE' 
FFSCAP= ' FEE FOR SERVICE/CAPITATION ' 
FROMULAR='FORMULARY ' 
MANFGNAM='NAME OF THE MANUFACTURER' 
NAWP1= ' AVERAGE WHOLESALE PRICE' 
NBDINGRE='BILLED INGREDIENT SUBMITTED BY PHARMACY' 
NCOPAYAM= ' COPAYMENT' 
NMEMAGE='AGE OF THE MEMBER' 
NPAIDAMT='AMOUNT PAID TO PHARMACY' 
NPAYINGR='AMOUNT PAID TO PHARMACY FOR INGREDIENT' 
NPROFFEE='FEE CHARGED BY PHARMACY FOR FILLING THE RX' 
NQTYDISP='TOTAL UNITS DISPENSED' 
NRXS='NUMBER OF PRESCRIPTION ' 
REGION='PLAN REGION' 
TYPE='HMO/PPO' 
NDAYSUPP= ' NUMBER OF DAYS SUPPLY' 
NELIG='NUMBER OF MEMBERS ELIGIBLE' 
NPHARMAM='COST OF RX TO PRO-MARK' 
TOTDELIG='NUMBER OF DAYS ELIGIBLE FOR MEMBER' 
SQCOPAY='SQRT(COPAYMENT)' 
LCOPAYAM='LOG(COPAYMENT)' 
SQDAYSUP='SQRT(NUMBER OF DAYS SUPPLY)' 
LDAYSUPP= ' LOG(NUMBER OF DAYS SUPPLY)' 
SQRTELIG= ' SQRT(NUMBER OF MEMBERS ELIGIBLE) ' 
LELIG='LOG(NUMBER OF MEMBERS ELIGIBLE) ' 
90 
( SQMEMAGE= ' SQRT(MEMBER AGE)' 
LMEMAGE='LOG(MEMBER AGE)' 
SQPHARAM='SQRT(COST OF RX TO PRO-MARK)' 
LPHARMAM='LOG(COST OF RX TO PRO-MARK)' 
SQTYDISP= ' SQRT(TOTAL UNITS DISPENSED)' 
LQTYDISP= ' LOG(TOTAL UNITS DISPENSED)' 
SQTOTDEL='SQRT(NUMBER OF DAYS ELIGIBLE FOR MEMBER)' 
LTOTDELI='LOG(NUMBER OF DAYS ELIGIBLE FOR MEMBER) ' 
RFTOTDEL= ' REFLECTED NUMBER OF DAYS ELIGIBLE FOR MEMBER ' 
SQRFTOTD= ' SQRT(REFLECTED NUMBER OF DAYS ELIGIBLE FOR MEMBER' 
LRFTOTDE='LOG(REFLECTED NUMBER OF DAYS ELIGIBLE FOR MEMBER ' 
INRFTOTD='INV(REFLECTED NUMBER OF DAYS ELIGIBLE FOR MEMBER ' 
SNAWP1='SQRT(NAWP1) ' 
LNAWP1='LOG(NAWP1) ' 
CMEMGEN1='DUMMY VAR. FOR GENDER' 
CCOPAYAM= ' CAT. VAR FOR COPAYMENT' 
LPHAR= ' LOCATION OF PHARMACY (STATE) ' 
CHAINCO='MODIFIED VAR. FOR PHARMACY TYPE' 
SUPPLY='MODIFIED VAR. FOR DAYS SUPPLY ' ; 
FROMULAR=FORMULAR; 
NAWP2=NAWP1; 
CGENNAME=SCAN(CGENNAME,1); 
IF NMEMAGE=996 THEN DELETE; 
IF TOTDELIG>366 THEN TOTDELIG=366; 
SQCOPAY=SQRT(NCOPAYAM); 
LCOPAYAM=LOG10(NCOPAYAM); 
SQDAYSUP=SQRT(NDAYSUPP); 
LDAYSUPP=LOG10(NDAYSUPP); 
SQRTELIG=SQRT(NELIG); 
LELIG=LOG10(NELIG); 
SQMEMAGE=SQRT(NMEMAGE); 
LMEMAGE=LOG10(NMEMAGE); 
SQPHARAM=SQRT(NPHARMAM); 
LPHARMAM=LOG10(NPHARMAM); 
SQTYDISP=SQRT(NQTYDISP); 
LQTYDISP=LOG10(NQTYDISP); 
SQTOTDEL=SQRT(TOTDELIG); 
LTOTDELI=LOG10(TOTDELIG); 
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( RFTOTDEL=367 - TOTDELIG; 
SQRFTOTD=SQRT(RFTOTDEL); 
LRFTOTDE=LOG10(RFTOTDEL); 
INRFTOTD=1/RFTOTDEL; 
SNAWP1=SQRT(NAWP1); 
LNAWP1 =LOG10 ( NAWP1); 
IF CMEMGEND=' F ' THEN MEMGEN1=0; 
IF CMEMGEND=' M' THEN MEMGEN1=1; 
LENGTH CCOPAYAM $10; 
IF O<=NCOPAYAM<=3 THEN CCOPAYAM= ' 0-3 ' ; 
IF 3<NCOPAYAM<=9 THEN CCOPAYAM=' >3-9 ' ; 
IF 9<NCOPAYAM<=12 THEN CCOPAYAM= '>9 -12 ' ; 
IF 12<NCOPAYAM THEN CCOPAYAM='> 12 ' ; 
LENGTH LPHAR $10; 
LPHAR=CSTATE; 
LENGTH CHAINCO $10; 
CHAINCO=CCHAINCO; 
IF CCHAINCO= ' 
ELSE CHAINCO='CH ' ; 
LENGTH SUPPLY $10; 
SUPPLY=NDAYSUPP; 
THEN CHAINCO='IN ' ; 
IF O<NDAYSUPP<=30 THEN SUPPLY= ' =>30 ' ; 
IF 31<=NDAYSUPP<=180 THEN SUPPLY= ' <30'; 
LENGTH STATE $10; 
IF CSTATE= ' AL ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' KY ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' MS' THEN STATE='OTHER'; 
IF CSTATE= ' TN ' THEN STATE= ' TN ' ; 
IF CSTATE= ' AK ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' AZ ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' CO ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' ID ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' MT' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' NM ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' ND ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' OR' THEN STATE='OTHER ' ; 
IF CSTATE= ' SD ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' UT ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' WA ' THEN STATE=' OTHER ' ; 
IF CSTATE=' WY' THEN STATE='OTHER ' ; 
IF CSTATE= ' CA ' THEN STATE= ' OTHER ' ; 
IF CST ATE= ' HI ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' NV ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' CT ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' ME' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' MA ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' NH ' THEN STATE= ' OTHER ' ; 
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( IF CSTATE='NY' THEN STATE= ' OTHER ' ; IF CSTATE= ' RI ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' VT ' THEN STATE =' OTHER ' ; 
IF CSTATE= ' DE ' THEN STATE=' OTHER ' ; 
IF CSTATE= ' DC ' THEN STATE= ' OTHER ' ; 
IF CSTATE= 'M D' THEN STATE=' OTHER ' ; 
IF CSTATE= 'NJ ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' PA ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' VA ' THE N STATE=' OTHER ' ; 
IF CSTATE= 'WV' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' FL ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' GA ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' NC ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' PR' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' SC ' THEN STATE=' OTHER ' ; 
IF CSTATE= ' VI ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' IL ' THEN STATE='OTHER ' ; 
IF CST ATE= ' IN ' THEN STATE= ' OTHER ' ; 
IF CSTATE= 'M I ' THEN STATE= ' OTHER ' ; 
IF CSTATE= 'M N' THEN STATE= ' OTHER ' ; 
IF CSTATE=' OH ' THE N STATE=' OTHER ' ; 
IF CSTATE = 'WI ' THE N STATE=' OTHER ' ; 
IF CSTATE= ' AR ' THEN STATE= ' OTHER'; 
IF CST ATE= ' IA ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' KS ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' LA ' THEN STATE= ' OTHER ' ; 
IF CSTATE= 'MO' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' NE ' THEN STATE= ' OTHER ' ; 
IF CSTATE= ' OK ' THEN STATE= ' OTHER ' ; 
IF CSTATE='TX' THEN STATE= ' OTHER ' ; 
LENGTH OCCUPAT1 $10; 
LABEL OCCUPAT1= ' MODIFIED VAR. FOR OCCUPATION'; 
IF COCCUPAT= ' 1 ' THEN OCCUPAT1= ' 1 ' ; 
IF COCCUPAT= ' 4 ' THEN OCCUPAT1= ' 4 ' ; 
IF COCCUPAT= ' 7 ' THEN OCCUPAT1 =' 7 ' ; 
IF COCCUPAT= ' 10' THEN OCCUPAT1= ' 10 ' ; 
IF COCCUPAT=' 11' THEN OCCUPAT1= ' 0THER ' ; 
IF COCCUPAT= ' 2 ' THEN OCCUPAT1 =' 0THER ' ; 
IF COCCUPAT= ' 6 ' THEN OCCUPAT1= ' 0THER ' ; 
IF COCCUPAT= ' 8 ' THEN OCCUPAT1= ' 0THER ' ; 
IF COCCUPAT= ' 9 ' THEN OCCUPAT1= ' 0THER ' ; 
IF COCCUPAT= ' 5 ' THEN OCCUPAT1= ' 0THER ' ; 
LABEL STATE1= ' DUMMY FOR LOCATION ' 
OCCUP1='DUMMY FOR MANFG. ' 
OCCUP2= ' DUMMY FOR HEALTH ' 
OCCUP3= ' DUMMY FOR S&S ' 
OCCUP4='DUMMY FOR MGMT .' ; 
93 
( IF STATE= ' TN' THEN STATE1=1; IF STATE=' OTHER ' THEN STATE1=0; 
IF OCCUPAT1='10' THEN OCCUP1=1; 
IF OCCUPAT1='10' THEN OCCUP2=0; 
IF OCCUPAT1='10' THEN OCCUP3=0; 
IF OCCUPAT1= ' 10' THEN OCCUP4=0; 
IF OCCUPAT1='4 ' THEN OCCUP1=0; 
IF OCCUPAT1='4 ' THEN OCCUP2=1; 
IF OCCUPAT1='4 ' THEN OCCUP3=0; 
IF OCCUPAT1='4' THEN OCCUP4=0; 
IF OCCUPAT1='7 ' THEN OCCUP1=0; 
IF OCCUPAT1='7' THEN OCCUP2=0; 
IF OCCUPAT1='7 ' THEN OCCUP3=1; 
IF OCCUPAT1='7' THEN OCCUP4=0; 
IF OCCUPAT1='1' THEN OCCUP1=0; 
IF OCCUPAT1='1' THEN OCCUP2=0; 
IF OCCUPAT1='1' THEN OCCUP3=0; 
IF OCCUPAT1='1 ' THEN OCCUP4=1; 
IF OCCUPAT1='0THER' THEN OCCUP1=0; 
IF OCCUPAT1= ' 0THER ' THEN OCCUP2=0; 
IF OCCUPAT1= ' 0THER' THEN OCCUP3=0; 
IF OCCUPAT1= ' 0THER' THEN OCCUP4=0; 
LABEL NMEMAGE1='CAT. VAR FOR AGE ' ; 
LENGTH NMEMAGE1 $15; 
IF O<=NMEMAGE<=5 THEN NMEMAGE1='1-5 ' ; 
IF 6<=NMEMAGE<=20 THEN NMEMAGE1='6-20'; 
IF 21<=NMEMAGE<=40 THEN NMEMAGE1= ' 21-40'; 
IF 41<=NMEMAGE<=64 THEN NMEMAGE1= ' 41-64 '; 
IF 65<=NMEMAGE THEN NMEMAGE1= '>65 ' ; 
LABEL CPD= ' COST PER DAY' 
SCPD='SQRT(COST PER DAY)' 
LCPD='LOG10(COST PER DAY)'; 
CPD=NPHARMAM/TOTDELIG; 
SCPD=SQRT(CPD); 
LCPD=LOG10(CPD); 
LABEL INTGENST= ' INTERACTION GENDER & STATE' 
INTGEN01= ' INTERACTION GENDER & OCCUPATION1' 
INTGEN02= ' INTERACTION GENDER & OCCUPATION2' 
INTGEN03='INTERACTION GENDER & OCCUPATION3' 
INTGEN04='INTERACTION GENDER & OCCUPATION4'; 
INTGENST=MEMGEN1*STATE1; 
INTGEN01=MEMGEN1*0CCUP1; 
INTGEN02=MEMGEN1*0CCUP2; 
INTGEN03=MEMGEN1*0CCUP3; 
INTGEN04=MEMGEN1*0CCUP4; 
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FORMAT CSTATE $CSTATE. CBRANDNA $CBRANDNA. 
CDOSEFOR $CDOSEFOR. CMEMGEND $MEMGEND. CDAWIND $CDAWIND. 
CMACIND $CMACIND. CPRODTYP $CPRODTYP. CGENPROD $CGENPROD. 
CGENIND $CGENIND. FFSCAP $FFSCAP. FROMULAR $FROMULAR. 
COCCUPAT $COCCUPAT. CCHAINCO $CCHAINCO.; 
RUN; 
PROC CONTENTS DATA=ALMAS.BETA2; 
RUN; 
PROC FREQ DATA=ALMAS.BETA2 ORDER=FREQ; 
TABLES CACCOUNT CBRANDNA CCARRIER CCATCODE CCHAINCO CDAWIND 
CDOSEFOR CGENIND CGENNAME CGENPROD CGROUP CLTC CMACIND 
CMCO CMEMGEND CNAME COCCUPAT CPRODTYP CREFILL CSTATE 
CSTRENGT FFSCAP FROMULAR MANFGNAM NDAYSUPP NQTYDISP 
NRXS REGION TYPE NCOPAYAM; 
RUN; 
PROC UNIVARIATE DATA=ALMAS.BETA2 NORMAL PLOT; 
VAR NCOPAYAM SQCOPAY LCOPAYAM NDAYSUPP SQDAYSUP LDAYSUPP 
NELIG SQRTELIG LELIG NMEMAGE SQMEMAGE LMEMAGE 
NPHARMAM SQPHARAM LPHARMAM NQTYDISP SQTYDISP LQTYDISP 
TOTDELIG SQTOTDEL LTOTDELI SQRFTOTD LRFTOTDE INRFTOTD 
NAWP1 SNAWP1 LNAWP1; 
RUN; 
PROC UNIVARIATE DATA=ALMAS.BETA2 NORMAL PLOT; 
VAR NPAYINGR; 
RUN; 
PROC UNIVARIATE DATA=ALMAS.BETA2 NORMAL PLOT; 
VAR CPD SCPD LCPD; 
RUN; 
PROC PLOT DATA=ALMAS.BETA2; 
PLOT SQPHARAM*LCOPAYAM SQPHARAM*SQDAYSUP SQPHARAM*LELIG 
SQPHARAM*NMEMAGE SQPHARAM*LQTYDISP SQPHARAM*TOTDELIG 
SQPHARAM*SNAWP1; 
RUN; 
DATA ALMAS.BETA3; 
SET ALMAS.BETA2; 
LABEL CMEMID1= ' PROCESS VARIABLE FOR MEMID ' 
CMEMID2='VARIABLE FOR SUBSCRIBER ONLY'; 
CMEMID1=SUBSTR(CMEMID,10,2); 
CMEMID2=CMEMID1; 
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IF CCARRIER='RIP001 ' AND CMEMID1 = ' ' THEN CMEMID2= ' 01 ' ; 
IF CCARRIER='TNC012' AND CMEMID1= ' E1 ' THEN CMEMID2='01 ' ; 
IF CCARRIER='TNC019' AND CMEMID1 =' e' THEN CMEMID2= '01 ' ; 
IF CCARRIER='TNC100 ' AND CMEMID1= ' 00 ' THEN CMEMID2='01 '; 
IF CCARRIER= ' TNC107 ' 
IF CCARRIER= ' TNC107 ' 
IF CCARRIER= ' TNC107 ' 
IF CCARRIER= ' TNC107 ' 
RUN; 
DATA ALMAS . BETA4; 
SET ALMAS.BETA3; 
IF CMEMID2= '01 ' ; 
LENGTH OCCUPAT1 $10; 
AND 
AND 
AND 
AND 
CACCOUNT= ' 716 ' AND CMEMID1= ' E' 
CACCOUNT= ' CORR ' AND CMEM ID1='00 ' 
CACCOUNT= ' CSA ' AND CMEMID1= ' E' 
CACCOUNT= ' GGCI ' AND CMEMID1='00 ' 
LABEL OCCUPAT1= 'MODIFIED VAR. FOR OCCUPATION ' ; 
IF COCCUPAT= ' 1 ' THEN OCCUPAT1= ' 1 ' ; 
IF COCCUPAT='4 ' THEN OCCUPAT1='4 ' ; 
IF COCCUPAT= ' 7 ' THEN OCCUPAT1='7 ' ; 
IF COCCUPAT= ' 10 ' THEN OCCUPAT1= ' 10 ' ; 
IF COCCUPAT= ' 11 ' THEN OCCUPAT1 =' 0THER ' ; 
IF COCCUPAT= ' 2 ' THEN OCCUPAT1='0THER ' ; 
IF COCCUPAT='6 ' THEN OCCUPAT1='0THER ' ; 
IF COCCUPAT='8 ' THEN OCCUPAT1= ' 0THER ' ; 
IF COCCUPAT= ' 9 ' THEN OCCUPAT1='0THER ' ; 
IF COCCUPAT= ' 5 ' THEN OCCUPAT1= ' 0THER ' ; 
LABEL CPD= ' COST PER DAY ' 
SCPD='SQRT(COST PER DAY) ' 
LCPD='LOG10(COST PER DAY) ' ; 
CPD=NPHARMAM/TOTDELIG; 
SC PD= SQRT (CPD) ; 
LCPD=LOG10(CPD); 
RUN; 
PROC UNIVARIATE DATA=ALMAS.BETA4 NORMAL PLOT; 
VAR CPD SCPD LCPD; 
RUN; 
PROC PRINT DATA=ALMAS.BETA4 (FIRSTOBS=1 OBS=100); 
VAR CCARRIER CACCOUNT CGROUP CMEMID CMEMID1 CMEMID2; 
RUN; 
PROC FREQ DATA=ALMAS.BETA4 ORDER=FREQ; 
THEN 
THEN 
THEN 
THEN 
TABLES CACCOUNT CBRANDNA CCARRIER CCATCODE CCHAINCO CDAWIND 
CDOSEFOR CGENIND CGENNAME CGENPROD CGROUP CLTC CMACIND 
CMCO CMEMGEND CNAME COCCUPAT CPRODTYP CREFILL CSTATE 
CSTRENGT FFSCAP FROIJULAR MANFGNAM NDAYSUPP NQTYDISP 
NRXS REGION TYPE; 
RUN; 
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CMEMID2= ' 01'; 
CMEMID2= ' 01'; 
CMEMID2= ' 01 ' ; 
CMEMID2= ' 01'; 
PROC UNIVARIATE DATA=ALMAS.BETA4 NORMAL PLOT; 
VAR NCOPAYAM SOCOPAY LCOPAYAM NDAYSUPP SQDAYSUP LDAYSUPP 
NELIG SQRTELIG LELIG NMEMAGE SQMEMAGE LMEMAGE 
NPHARMAM SQPHARAM LPHARMAM NOTYDISP SOTYDISP LOTYDISP 
TOTDELIG SQTOTDEL LTOTDELI SQRFTOTD LRFTOTDE INRFTOTD 
NAWP1 SNAWP1 LNAWP1; 
RUN; 
PROC PLOT DATA=ALMAS . BETA4; 
PLOT LPHARMAM*LCOPAYAM LPHARMAM*SQDAYSUP LPHARMAM*LELIG 
LPHARMAM*NMEMAGE LPHARMAM*LOTYDISP LPHARMAM*TOTDELIG 
LPHARMAM*SNAWP1; 
RUN; 
PROC CORR DATA=ALMAS.BETA2; 
VAR LCOPAYAM SQDAYSUP LELIG NMEMAGE SOPHARAM 
LQTYDISP TOTDELIG SNAWP1; 
TITLE ' CORR. MATRIX FOR DATABASE WITHOUT RIPAE ' ; 
RUN; 
PROC CORR DATA=ALMAS.BETA4; 
VAR LCOPAYAM SQDAYSUP LELIG NMEMAGE LPHARMAM 
LOTYDISP TOTDELIG SNAWP1; 
TITLE ' CORR . MATRIX FOR ONLY SUBSCRIBERS'; 
RUN; 
PROC FREQ DATA=ALMAS.BETA2; 
TABLES STATE1 OCCUP1 OCCUP2 OCCUP3 OCCUP4; 
RUN; 
PROC REG DATA=ALMAS . BETA2; 
MODEL LCPD=NMEMAGE MEMGEN1 STATE1 OCCUP1 OCCUP2 OCCUP3 
OCCUP4 INTGENST INTGEN01 INTGEN02 INTGEN03 INTGEN04 I STB 
COLLIN TOL VIF; 
TITLE1 ' REGRESSION USING DEMOGRAPHIC VARS . ' ; 
RUN; 
PROC REG DATA=ALMAS . BETA2; 
MODEL LCPD=TOTDELIG LELIG SNAWP1 LCOPAYAM 
SQDAYSUP LQTYDISP/ STB 
COLLIN TOL VIF; 
TITLE1 ' REGRESSION USING VAR . FOR PLAN CHARACTERISTICS'; 
RUN; 
PROC REG DATA=ALMAS.BETA2; 
MODEL LCPD=NMEMAGE MEMGEN1 STATE1 OCCUP1 OCCUP2 OCCUP3 
OCCUP4 TOTDELIG LELIG SNAWP1 LCOPAYAM 
SQDAYSUP LQTYDISP/ STB 
COLLIN TOL VIF; 
TITLE1 ' REGRESSION USING ALL VARS. ' ; 
RUN; 
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PROC FREQ DATA=ALMAS.BETA2; 
TABLES NMEMAGE1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS NMEMAGE1; 
MODEL LCPD=NMEMAGE1; 
MEANS NMEMAGE1/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS NMEMAGE1; 
MODEL LCPD=NMEMAGE1 LELIG SQDAYSUP SNAWP1 
NMEMAGE1*LELIG NMEMAGE1*SQDAYSUP 
NMEMAGE1*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS NMEMAGE1; 
MODEL LCPD=NMEMAGE1 SQDAYSUP/SOLUTION; 
LSMEANS NMEMAGE1/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS NMEMAGE1; 
MODEL LCPD=NMEMAGE1 LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS NMEMAGE1; 
MODEL LCPD=NMEMAGE1 SNAWP1 /S_OLUTION; 
LSMEANS NMEMAGE1/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS NMEMAGE1; 
MODEL LCPD=NMEMAGE1 SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS NMEMAGE1/STDERR; 
RUN; 
PROC REG DATA=ALMAS.BETA2; 
MODEL SQPHARAM=NMEMAGE TOTDELIG LELIG SNAWP1 LCOPAYAM 
SQDAYSUP LQTYDISP MEMGEN1/ STB 
COLLIN TOL VIF; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS COCCUPAT; 
MODEL LCPD=COCCUPAT; 
MEANS COCCUPAT/TUKEY ALPHA=.01; 
RUN; 
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I 
' 
PROC GLM DATA=ALMAS.BETA4; 
CLASS COCCUPAT; 
MODEL LCPD=COCCUPAT NMEMAGE LELIG SQDAYSUP SNAWP1 
COCCUPAT*NMEMAGE COCCUPAT*LELIG COCCUPAT*SQDAYSUP 
COCCUPAT*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS COCCUPAT; 
MODEL LCPD=COCCUPAT NMEMAGE /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS COCCUPAT; 
MODEL LCPD=COCCUPAT LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS COCCUPAT; 
MODEL LCPD=COCCUPAT SQDAYSUP/SOLUTION; 
LSMEANS COCCUPAT/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS COCCUPAT; 
MODEL LCPD=COCCUPAT SNAWP1 /SOLUTION; 
LSMEANS COCCUPAT/STDERR; 
RUN; 
PROC GLM DATA=ALMAS . BETA4; 
CLASS COCCUPAT; 
MODEL LCPD=COCCUPAT SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS COCCUPAT/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1; 
MODEL LCPD=OCCUPAT1; 
MEANS OCCUPAT1/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1; 
MODEL LCPD=OCCUPAT1 NMEMAGE LELIG SQDAYSUP SNAWP1 
OCCUPAT1*NMEMAGE OCCUPAT1*LELIG OCCUPAT1*SQDAYSUP 
OCCUPAT1*SNAWP1; 
RUN; 
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PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1; 
MODEL LCPD=OCCUPAT1 NMEMAGE / SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1; 
MODEL LCPD=OCCUPAT1 LELIG / SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1; 
MODEL LCPD=OCCUPAT1 SQDAYSUP / SOLUTION; 
LSMEANS OCCUPAT1/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1; 
MODEL LCPD=OCCUPAT1 SNAWP1 / SOLUTION; 
LSMEANS OCCUPAT1/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1; 
MODEL LCPD=OCCUPAT1 SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS OCCUPAT1/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FFSCAP; 
MODEL LCPD=FFSCAP; 
MEANS FFSCAP/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FFSCAP; 
MODEL LCPD=FFSCAP NMEMAGE LELIG SQDAYSUP SNAWP1 
FFSCAP*NMEMAGE FFSCAP*LELIG FFSCAP*SQDAYSUP 
FFSCAP*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FFSCAP; 
MODEL LCPD=FFSCAP SQDAYSUP/SOLUTION; 
LSMEANS FFSCAP/STDERR; 
RUN; 
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PROC GLM DATA=ALMAS.BETA2; 
CLASS FFSCAP; 
MODEL LCPD=FFSCAP NMEMAGE /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FFSCAP; 
MODEL LCPD=FFSCAP LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FFSCAP; 
MODEL LCPD=FFSCAP SNAWP1 /SOLUTION; 
LSMEANS FFSCAP/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FFSCAP; 
MODEL LCPD=FFSCAP SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS FFSCAP/STDERR; 
RUN; 
PROC FREQ DATA=ALMAS.BETA2; 
TABLES CCOPAYAM LPHAR CHAINCO SUPPLY; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM; 
MODEL LCPD=CCOPAYAM; 
MEANS CCOPAYAM/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM; 
MODEL LCPD=CCOPAYAM NMEMAGE LELIG SQDAYSUP SNAWP1 
CCOPAYAM*NMEMAGE CCOPAYAM*LELIG CCOPAYAM*SQDAYSUP 
CCOPAYAM*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM; 
MODEL LCPD=CCOPAYAM SQDAYSUP/SOLUTION; 
LSMEANS CCOPAYAM/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM; 
MODEL LCPD=CCOPAYAM NMEMAGE /SOLUTION; 
RUN; 
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PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM; 
MODEL LCPD=CCOPAYAM LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM; 
MODEL LCPD=CCOPAYAM SNAWP1 /SOLUTION; 
LSMEANS CCOPAYAM/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM; 
MODEL LCPD=CCOPAYAM SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS CCOPAYAM/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FROMULAR; 
MODEL LCPD=FROMULAR; 
MEANS FROMULAR/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FROMULAR; 
MODEL LCPD=FROMULAR NMEMAGE LELIG SQDAYSUP SNAWP1 
FROMULAR*NMEMAGE FROMULAR*LELIG FROMULAR*SQDAYSUP 
FROMULAR*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FROMULAR; 
MODEL LCPD=FROMULAR SQDAYSUP/SOLUTION; 
LSMEANS FROMULAR/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FROMULAR; 
MODEL LCPD=FROMULAR NMEMAGE / SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FROMULAR; 
MODEL LCPD=FROMULAR LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS FROMULAR; 
MODEL LCPD=FROMULAR SNAWP1 /SOLUTION; 
LSMEANS FROMULAR/STDERR; 
RUN; 
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PROC GLM DATA=ALMAS.BETA2; 
CLASS FROMULAR; 
MODEL LCPD=FROMULAR SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS FROMULAR/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS STATE; 
MODEL LCPD=STATE; 
MEANS STATE/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS STATE; 
MODEL LCPD=STATE NMEMAGE LELIG SQDAYSUP SNAWP1 
STATE*NMEMAGE STATE*LELIG STATE*SQDAYSUP 
STATE*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS STATE; 
MODEL LCPD=STATE SQDAYSUP/SOLUTION; 
LSMEANS STATE/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS STATE; 
MODEL LCPD=STATE NMEMAGE /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS . BETA2; 
CLASS STATE; 
MODEL LCPD=STATE LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS STATE; 
MODEL LCPD=STATE SNAWP1 /SOLUTION; 
LSMEANS STATE/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS STATE; 
MODEL LCPD=STATE SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS STATE/STDERR; 
RUN; 
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PROC GLM DATA=ALMAS.BETA2; 
CLASS CMEMGEND; 
MODEL LCPD=CMEMGEND; 
MEANS CMEMGEND/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CMEMGEND; 
MODEL LCPD=CMEMGEND NMEMAGE LELIG SQDAYSUP SNAWP1 
CMEMGEND*NMEMAGE CMEMGEND*LELIG CMEMGEND*SQDAYSUP 
CMEMGEND*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CMEMGEND; 
MODEL LCPD=CMEMGEND SQDAYSUP / SOLUTION; 
LSMEANS CMEMGEND/STDERR; 
RUN; 
PROC GLM DATA=ALMAS . BETA2; 
CLASS CMEMGEND; 
MODEL LCPD=CMEMGEND NMEMAGE / SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS . BETA2; 
CLASS CMEMGEND; 
MODEL LCPD=CMEMGEND LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS . BETA2; 
CLASS CMEMGEND; 
MODEL LCPD=CMEMGEND SNAWP1 /SOLUTION; 
LSMEANS CMEMGEND/STDERR; 
RUN; 
PROC GLM DATA=ALMAS . BETA2; 
CLASS CMEMGEND; 
MODEL LCPD=CMEMGEND SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS CMEMGEND/STDERR; 
RUN; 
PROC GLM DATA=ALMAS . BETA2; 
CLASS CHAINCO; 
MODEL LCPD=CHAINCO; 
MEANS CHAINCO/TUKEY ALPHA=.01; 
RUN; 
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PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO; 
MODEL LCPD=CHAINCO NMEMAGE LELIG SQDAYSUP SNAWP1 
CHAINCO*NMEMAGE CHAINCO*LELIG CHAINCO*SQDAYSUP 
CHAINCO*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO; 
MODEL LCPD=CHAINCO SQDAYSUP/SOLUTION; 
LSMEANS CHAINCO/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO; 
MODEL LCPD=CHAINCO NMEMAGE /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO; 
MODEL LCPD=CHAINCO LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS . BETA2; 
CLASS CHAINCO; 
MODEL LCPD=CHAINCO SNAWP1 /SOLUTION; 
LSMEANS CHAINCO/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO; 
MODEL LCPD=CHAINCO SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS CHAINCO/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO STATE ; 
MODEL LCPD=CHAINCO STATE CHAINCO*STATE; 
MEANS CHAINCO STATE CHAINCO*STATE/TUKEY ALPHA=.01; 
RUN; 
PRDC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO STATE; 
MODEL LCPD=CHAINCO STATE CHAINCO*STATE NMEMAGE 
LELIG SQDAYSUP SNAWP1 
CHAINCO*STATE*NMEMAGE CHAINCO*STATE*LELIG 
CHAINCO*STATE*SQDAYSUP CHAINCO*STATE*SNAWP1; 
RUN; 
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PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO STATE; 
MODEL LCPD=CHAINCO STATE CHAINCO*STATE SODAYSUP/SOLUTION; 
LSMEANS CHAINCO STATE CHAINCO*STATE/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO STATE; 
MODEL LCPD=CHAINCO STATE CHAINCO*STATE NMEMAGE /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO STATE; 
MODEL LCPD=CHAINCO STATE CHAINCO*STATE LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO STATE; 
MODEL LCPD=CHAINCO STATE CHAINCO*STATE SNAWP1 /SOLUTION; 
LSMEANS CHAINCO STATE CHAINCO*STATE/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CHAINCO STATE; 
MODEL LCPD=CHAINCO STATE CHAINCO*STATE SNAWP1 SODAYSUP/SOLUTION; 
LSMEANS CHAINCO STATE CHAINCO*STATE/STDERR; 
RUN; 
PROC GLM DATA=ALMAS . BETA4; 
CLASS OCCUPAT1 CMEMGEND; 
MODEL LCPD=OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND; 
MEANS OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1 CMEMGEND; 
MODEL LCPD=OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND NMEMAGE 
LELIG SODAYSUP SNAWP1 
OCCUPAT1*CMEMGEND*NMEMAGE OCCUPAT1*CMEMGEND*LELIG 
OCCUPAT1*CMEMGEND*SODAYSUP OCCUPAT1*CMEMGEND*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1 CMEMGEND; 
MODEL LCPD=OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND SODAYSUP/SOLUTION; 
LSMEANS OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND/STDERR; 
RUN; 
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PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1 CMEMGEND; 
MODEL LCPD=OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND NMEMAGE /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1 CMEMGEND; 
MODEL LCPD=OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1 CMEMGEND; 
MODEL LCPD=OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND SNAWP1 /SOLUTION; 
LSMEANS OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA4; 
CLASS OCCUPAT1 CMEMGEND; 
MODEL LCPD=OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND SNAWP1 SQDAYSUP/SOLUTION; 
LSMEANS OCCUPAT1 CMEMGEND OCCUPAT1*CMEMGEND/STDERR; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM SUPPLY; 
MODEL LCPD=CCOPAYAM SUPPLY CCOPAYAM*SUPPLY; 
MEANS CCOPAYAM SUPPLY CCOPAYAM*SUPPLY/TUKEY ALPHA=.01; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM SUPPLY; 
MODEL LCPD=CCOPAYAM SUPPLY CCOPAYAM*SUPPLY 
NMEMAGE LELIG SNAWP1 
CCOPAYAM*SUPPLY*NMEMAGE CCOPAYAM*SUPPLY*LELIG 
CCOPAYAM*SUPPLY*SNAWP1; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM SUPPLY; 
MODEL LCPD=CCOPAYAM SUPPLY CCOPAYAM*SUPPLY NMEMAGE /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM SUPPLY; 
MODEL LCPD=CCOPAYAM SUPPLY CCOPAYAM*SUPPLY LELIG /SOLUTION; 
RUN; 
PROC GLM DATA=ALMAS.BETA2; 
CLASS CCOPAYAM SUPPLY; 
MODEL LCPD=CCOPAYAM SUPPLY CCOPAYAM*SUPPLY SNAWP1 /SOLUTION; 
LSMEANS CCOPAYAM SUPPLY CCOPAYAM*SUPPLY/STDERR; 
RUN; 
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